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ABSTRACT 
HUEI-AN CHU: A Framework of Risk-Based Decision Making by Characterizing 
Variability and Uncertainty Probabilistically: Using Arsenic in Dinking Water as an Example 
(Under the direction of Dr. Douglas J. Crawford-Brown) 
 
Risk-based regulatory decisions generally apply a margin of safety meant to guard 
against underestimation of risk in the face of inter-subject variability and uncertainty. Since 
these two components often are unknown or only vaguely characterized, the decisions 
involved usually employ conservative default assumptions concerning the margin of safety, 
resulting in regulatory limits that may be more (or less) health protective than necessary if 
variability and uncertainty could be characterized probabilistically. As a result, it remains 
impossible in most cases to determine the degree of protectiveness inherent in a standard. 
The debate about maximum contaminant levels (MCLs) of arsenic is an example. At present, 
we can only get a vague idea that lowering MCLs results in larger margins of safety, but at 
the expense of greater compliance costs. If the magnitude of this margin of safety is not taken 
into account, it is possible that an MCL may be established based on a significantly larger 
margin of safety than is necessary, reasonable or consistent with that applied to other 
contaminants. Thus an unnecessarily expensive treatment policy may be selected. 
In this study, a new framework of probabilistic risk-based decision making was 
developed. A meta-analysis was conducted for arsenic in drinking water by combining 
several epidemiological studies from various regions (such as Taiwan, US, Argentina, Chile 
and Finland). Then the results of the meta-analysis were incorporated into the framework to 
 iii
 characterize the margin of safety through variability and uncertainty analyses. The final 
product of this study is a method of probabilistic risk assessment that better deals with 
variability and uncertainty issues. This risk assessment methodology can help decision-
makers make optimal determinations on regulatory limits for a contaminant that adequately 
protect human health with an ample margin of safety at a more reasonable cost than currently 
is the case. 
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CHAPTER 1 INTRODUCTION AND STATEMENT OF THE RESEARCH 
QUESTIONS 
 
1.1. Basic Statement 
Risk-based regulatory decisions generally apply a margin of safety (MOS) meant to 
guard against underestimation in the face of inter-subject variability and uncertainty.  Since 
these two components often are unknown or only vaguely characterized, the decisions 
involved usually employ conservative default assumptions concerning the margin of safety, 
resulting in regulatory limits that may be more (or less) health protective than necessary if 
variability and uncertainty could be characterized probabilistically.  As a result, it remains 
impossible in most cases to determine the degree of protectiveness inherent in a standard.  
Therefore, if we had good methods of probabilistic risk assessment better dealing with 
variability and uncertainty issues, we might be able to develop regulatory limits on a 
contaminant concentration that adequately protect human health with an ample margin of 
safety at a more reasonable cost than currently is the case. 
In this study, I have focused on the following general questions: 
? What is the current decision-making framework used in risk-based decision-making, and 
what is the role of risk assessment within this framework? 
? What is the role of margin of safety in risk-based decision-making framework?  Is there 
any way that the margin of safety can be quantified appropriately using probabilistic 
methods? 
 
 ? What would decisions be like under the new framework employing fully probabilistic 
methods? 
? How can the assessment and characterization of uncertainty and variability in risk 
assessment be improved under the new framework? 
? When variability and uncertainty are viewed probabilistically, how much does it cost to 
increase the margin of safety or confidence (in public health protection) when 
strengthening regulatory limits on concentrations in environmental media? 
 
1.2. Arsenic as a Case Study 
I chose inorganic arsenic in drinking water as the example for my framework because 
“arsenic is a good example of a substance for which better scientific information is needed to 
improve risk assessment needed for regulatory decisions” (Chappell et al., 1997).  Ingestion 
of drinking water containing inorganic arsenic has become a matter of great public concern, 
both in the United States and globally.  Inorganic arsenic in drinking water can exert toxic 
effects after acute (short-term) or chronic (long-term) exposures.  These health effects 
include cancerous effects (bladder, lung and skin cancer, and probably kidney and liver 
cancer) and non-cancerous effects (cardiovascular, pulmonary, immunological, neurological 
and endocrine such as diabetes) (NRC, 1999). 
The U.S. EPA (USEPA, 2001) reconsidered its arsenic MCL (Maximum 
Contaminant Level) and proposed potential MCLs of 3, 5, 10 and 20 µg/L (ppb), lowered 
from the original one of 50 µg/L.  EPA finally proposed an enforceable MCL of 10µg/L 
based on NRC reports (NRC, 1999; NRC, 2001) and application of default uncertainty 
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 factors to provide an adequate margin of safety.  This level was also determined to be 
feasible technologically and economically. 
However, arsenic MCLs continue to provoke scientific debate because of the 
variability and uncertainty issues in risk assessment.  These issues include: (Frumkin and 
Thun, 2001) (1) limitations in the data concerning the risk at low doses of arsenic; (2) 
uncertainty about the appropriate mathematical models for estimating the risk at low doses 
based on data obtained from higher doses; (3) identification of any sensitive subpopulation 
potentially unprotected under new MCLs because of variability of health effects within the 
population; and (4) lack of a methodology to quantify probabilistically the margin of safety.  
These controversies are actually related to each other and are associated with 
imperfections in the current framework of risk-based decision making.  Without appropriate 
models from animal studies, and because no statistical evidence of arsenic risks has been 
observed at levels found in U.S. drinking water systems, U.S. EPA and NRC have relied on 
the epidemiological data from high arsenic areas such as Taiwan (Chen et al., 1988 and 1992 
and Wu et al., 1989) to estimate the risk to U.S. populations at lower arsenic levels.  These 
data are criticized for possibly overstating the risk of arsenic ingestion in the U.S. in part 
because they do not reflect differences in lifestyle, dietary habits, nutriential status and 
genetics.  It might not be appropriate to use the Taiwanese data for the U.S. population 
without considering previous criticisms. 
The use of a linear procedure to extrapolate from a higher, observed data range to a 
lower range beyond observation might also overestimate the risks.  The U.S. EPA assumed 
linearity for the dose-response assessments for arsenic at low doses, although some research 
showed that ‘when there is adequate data to characterize the mode of action, the shape of the 
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 dose-response relationship may prove to be sub-linear below the observed range of the high 
level arsenic in Taiwan’ (NRC, 1999). 
Moreover, there are several sources of uncertainty and variability involving the risk 
assessment for arsenic in drinking water.  Uncertainty results from lack of knowledge in the 
underlying science.  Variability comes from the differences among subjects in genetics, 
metabolism, diet, health status and gender.  Because of the variability, some individuals or 
subpopulations may be more sensitive to contaminants and have higher risks than others.  
Therefore, MCLs are selected to provide a margin of safety for the protection of public health 
even in the face of inter-subject variability and uncertainty.  This margin of safety considers 
factors such as inter-subject variability, quality of the database, as well as the need to 
extrapolate across species.  However, the margin of safety is usually un-quantified; it remains 
impossible in most cases to determine the degree of protectiveness inherent in a standard 
using a particular margin of safety (i.e. the fraction of the population protected and the 
degree of confidence in this protection).  Taking arsenic as an example, right now we can 
only get a vague idea that lower MCLs result in larger margins of safety, but at the expense 
of greater compliance costs.  If the magnitude of this margin of safety is not taken into 
account, it is possible that an MCL may be established based on a significantly larger margin 
of safety than is necessary, reasonable or consistent with that applied to other contaminants. 
Thus an unnecessarily expensive treatment policy may be selected. 
 
1.3. Study Purposes and Research Products 
The first study purpose is to incorporate meta-analysis and to improve the current 
dose-response assessment.  The other main purpose in this study is to understand the margin 
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 of safety for arsenic as it relates to uncertainty and variability, and to understand how an 
increasing margin of safety relates to the cost of a regulation.  In other words, the goal is to 
better characterize uncertainty and variability in risk assessment, i.e. to improve the 
methodology of risk assessment, focusing on the variability and uncertainty issues.  My 
research goal is develop a new framework of risk-based decision-making by characterizing 
probabilistically the variability and uncertainty in risk assessment, using arsenic as an 
example. 
Besides the general questions listed in the beginning, my research questions for the 
first study purpose include the following: 
? In the observational range of available data, can meta-analysis be an appropriate tool to 
resolve the discrepancies among epidemiological data and get a reasonable generalized 
dose-response relationship between arsenic intake and cancer risk? 
? What are the uncertainty and variability distributions of risk for different MCLs of 
arsenic?  How much confidence do we have that a given MCL will still produce 
acceptable risk for a reasonable fraction of the population? 
? Combining the two questions above, what is the price of this increased confidence?  That 
is, what is the incremental cost associated with an incremental increase in the margin of 
safety, characterized by an increase in confidence and fraction of protected population? 
The final product is a framework of risk-based decision-making to improve the 
characterization of margin of safety and help to select optimal regulatory regulation limits 
(i.e. arsenic MCLs) that produce reasonable confidence in public health protection at 
reasonable cost. 
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CHAPTER 2 LITERATURE REVIEW 
 
2.1. Current Framework of Risk-Based Decision-Making 
 
2.1.1. Introduction 
 
2.1.1.1. Risk 
The definition of risk is “the probability that an individual will suffer injury, disease, 
or death under a specific set of circumstances” (Moeller, 1997), or the probability and 
magnitude of suffering harm from any environmental problem. There are two dimensions 
regarding risk: (1) the probability or likelihood of the harm; (2) the severity of the harm, its 
magnitude or significance.  The risk of concern in environmental policy is mostly from 
contamination of air, soil and water (Fiorino, 1995). 
Generally, there are three major activities in the study of risk: (1) Risk analysis; (2) 
Risk assessment and (3) Risk management.  Risk analysis is the process of breaking down 
the concepts or ideas of a problem; for example, defining what is to be meant by the 
probability of getting cancer and how confidence is to be used in estimating this probability.  
Risk assessment is the step of assigning values or numbers to the concepts; for example, 
calculating the specific probability of getting cancer.  And risk management is the selection 
of a course of action to reduce risk by integrating the risk assessment results with a variety of 
other information, such as feasibility and cost. 
 
 2.1.1.2. Risk-Based Decision-Making in Environmental Policy 
Risk assessment as well as economic analysis (cost-benefit analysis, specifically) 
serve as the analytical basis for environmental policy-making (Fiorino, 1995).  According to 
Executive Order 128166 (Federal Register, 1993), it is required that all federal agencies 
compare the risks of each regulatory action and provide cost-benefit analyses of the impacts 
of the proposed actions when developing new regulations (Moeller, 1997). 
Risk assessment can be divided into the following two categories: human health risk 
assessment and ecological risk assessment:  The object of concern of the former one is 
people and their well-being, while the object of concern of the latter one is expanded to other 
animals and plants, as well as the environment itself (Fiorino, 1995). 
In a summary, risk assessment is usually used in regulatory decision-making for the 
following purposes (Russell and Gruber, 1987): 
(1) As a scientific basis 
Risk assessment helps the EPA to present scientific and rational evidence for the 
growing burden of proof necessary to defend its regulatory proposals in court.  “Risk” also 
offers a scientific language by which to rationalize the regulatory decisions.  With the 
information from risk assessment, policy makers can select target pollutants for regulation 
and decide how stringently they want to control the various sources that contribute to a 
particular problem, and decide what actions provide “safety”; i.e., what degree of residual 
risk to accept in particular circumstances.  
(2) Set priorities for regulation 
Risk assessment helps EPA to set priorities for regulation of chemicals of potential 
concern and evaluate various strategies to manage risks.  Quantitative risk-assessment 
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 techniques were developed since the mid-1970s, and were used to set priorities among 
pesticides, drinking water contaminants, and other toxic chemicals and to justify regulation.  
After setting the priorities, limited social and government resources can be directed against 
the most significant risks. 
(3) Site-specific risk assessment 
Risk assessment helps to make site-specific decisions by considering the nature of the 
pollutant, the sensitivity of the environmental setting, and the availability of control questions.  
The most notable example of the application of risk assessment in this context is the 
Superfund Program. 
The current framework of risk-based decision-making is shown in Figure 2-1. 
 
Figure 2-1. Framework of Risk-based Decision-making (NRC, 1983). 
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 2.1.2. Methodology of Risk Assessment 
Risk can be expressed qualitatively or quantitatively.  An example of the former is 
EPA’s five categories for toxic agent (A - E), assigned depending on an agent’s potential for 
causing cancer in humans.  Arsenic has been categorized in list A, which is “known to be 
human carcinogens” (Frumkin and Thun, 2001).  Risk can also be expressed quantitatively; 
for example, probabilistic risk assessment expresses risk as a probability ranging from zero 
(certainty that harm will not occur) to one (certainty that harm will occur)  (Moeller, 1997). 
This research focused on quantitative risk assessment. 
 
2.1.2.1. Procedures of Quantitative Risk Assessment and the Scientific Basis 
The four procedures of quantitative risk assessment and the scientific basis are 
explained in the following paragraphs and summarized in Figure 2-2 (NRC, 1983). 
 
 
Figure 2-2. Components of risk assessment procedures (Moeller, 1997). 
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  (1) Hazard identification 
This procedure produces a qualitative judgment as to whether an agent has any 
potential to cause adverse health effects following exposure.  The question asked in this step, 
for example, is “does arsenic cause adverse health problems in humans through drinking 
water?”  The evidence can usually be derived from four general classes of information, 
including epidemiological data, animal-bioassay data, short-term in vitro assays, and 
comparisons of molecular structure.  Their importance in estimating risk to humans is in 
roughly decreasing order. (Crawford-Brown, 1999)  The EPA’s integrated risk information 
system (IRIS) can be a source for information about the potential toxicity of an agent. 
 
(2) Exposure assessment  
This procedure identifies populations exposed to the toxicant, describes their 
composition and size, and examines the routes, magnitudes, frequencies, and durations of 
such exposures.  Example questions in this procedure are: “what is the concentration of 
arsenic in groundwater?” and “what are the major exposure pathways of arsenic to human 
populations?” 
The first task in this step is to determine the concentration of the chemical to which 
humans are exposed.  This may be done by direct measurement or by a model if exposure 
data are incomplete or cannot be obtained directly.  The second task is to determine which 
group in the population may be exposed and if there is any subgroup in the population which 
is more susceptible to the exposure.  In the situation of exposure to a mixture of carcinogens, 
if data are unavailable, synergistic effects are often ignored or accounted for by the use of 
various safety factors. 
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 (3) Dose-response assessment  
This procedure estimates the relationship between dose and response quantitatively.  
The estimation can be based on epidemiological observations, animal data, or studies of 
mechanisms of action.  A typical question is: “what is the relationship between arsenic intake 
(dose) and incidence of cancer?”  Figure 2-2 presents two possible dose-response curves.  If 
useful human data are absent, a model for animal-to-human dose extrapolation will be used.  
If available data (epidemiological or animal) are only available at high dose, a model for low-
dose extrapolation will be used. 
                          
Figure 2-3. Dose-response relationship: linear non-threshold dose-response curve (left) 
and nonlinear threshold dose-response curve (right) (Moeller, 1997). 
 
(4) Risk characterization 
This procedure presents the policy-maker with an overall conclusion about the 
magnitude of risk, the variability of risk in the exposed population, and confidence in 
estimates of risk.  The assumptions underlying the assessment of uncertainty are also 
provided in this step. 
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 2.1.2.2. Risk Assessment Guidelines 
To avoid inconsistent assumptions and value judgments by different programs within 
the EPA, several Risk Assessment Guidelines have been provided as a consistent approach 
across programs.  The functions of this kind of guideline include informing EPA risk 
assessors on the best available science and risk assessment techniques, establishing a 
standard for quality of work and comparison of studies, providing for consistency and orderly 
decision-making, helping inform the public about how scientific judgments and assumptions 
have been incorporated into risk assessments, and helping show where additional research 
and analysis might be necessary.  In a word, they can provide EPA staff and decision makers 
with guidance for developing and using risk assessments, and provide basic information to 
the public about the Agency’s risk assessment methods. However, this kind of guideline is 
not an official regulation, and represents neither a perfect methodology nor an ideal 
consensus among scientists (USEPA, 1996; USEPA, 1999; USEPA, 2003). 
 
 
2.1.3. Flaws in the Current Framework of Risk-Based Decision-Making 
 
2.1.3.1. Precautionary Principle 
One of the critiques of the current risk assessment framework is that it is overly 
conservative due to the precautionary principle.  The definition of the precautionary principle 
is: “when information about potential risks is incomplete, base decisions about the best way 
to manage or reduce risks on a preference for avoiding unnecessary health risks instead of 
unnecessary economic expenditures”.  Based on this “better to be safe than sorry” principle, 
the most conservative models and assumptions are usually selected for use in risk assessment, 
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 and EPA usually selects an MCL or regulatory limit to provide a large margin of safety 
(MOS) for the protection of public health to reflect the quality of the database, inter-subject 
variability and uncertainty; as a result, the compliance cost may be high. 
 
2.1.3.2. Unsound Scientific Basis of Risk Assessment 
Another critique is that risk assessment may not provide sound/good science for 
environmental policy because of uncertainty and variability factors.  An NRC report (NCR, 
1994) listed the following potential flaws in the scientific bases for risk assessment: 
(1) Default assumptions adopted when evidence is not sufficient may have been unduly 
conservative. 
(2) Default options may have become too rigid, with an unnecessarily large barrier to the 
adoption of new, more scientifically defensible, assumptions. 
(3) Aspects of risk established as significant in science (e.g. synergisms/antagonisms) are 
missing from the risk assessment process. 
(4) Uncertainties in risk estimates are inadequately described and knowledge may have been 
insufficient to justify quantifying risk. 
(5) Risk estimates obtained under conservative assumptions for screening may have been 
applied to final, risk-based, decisions. 
(6) Results of risk assessments may have been given too little, or too much, weight of 
decisions. 
In a word, the default assumptions and extrapolation methodology (i.e. linearity 
assumption in low-dose extrapolation) used in EPA’s risk assessments have been criticized 
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 based on the claim that they are unsupported scientifically, raise needless public fears and 
waste money on costly and unnecessary protective measures. 
 
2.1.3.3. Variability and Uncertainty Issues in Risk Assessment 
Another flaw of the conventional framework of risk-based decision making is the 
inability to characterize the variability and uncertainty well.  “Variability means the 
distribution of some real quantity among things or people even after the application of perfect 
measurement techniques, whereas uncertainty is a description of the imperfection of our 
information about a parameter (including a parameter describing real variability)” or lack of 
knowledge in the underlying science (Hattis et al., 1999).  For example, inter-subject 
variations in factors contributing to risk may include genetics, metabolism, diet, health status, 
nutrition, gender, and other possible factors, whereas  uncertainty may result from model 
choice.  
Considering variability and uncertainty issues in risk assessment, regulatory policy 
has to apply a “Margin of Safety” as part of regulatory rationality.  In other words, margins 
of safety are generally applied to guard against underestimation in the face of inter-subject 
variability and uncertainty.  Therefore, regulatory decisions usually employ conservative 
default assumptions to guard against inadequate margin of safety in the face of variability 
and uncertainty.  This may result in regulatory limits that may be more (or less) health 
protective than necessary.  And this also leads to criticism about the margin of safety because 
it is impossible to estimate the magnitude of that margin. 
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 2.1.4. Conclusion 
Considering these flaws in the current framework, arsenic in drinking water may be a 
good case study to improve the risk assessment methodology and the whole risk-based 
regulatory decision-making (Chappell et al., 1997).  The controversies in the arsenic case are 
due to imperfections in the current framework of risk-based decision making.  If the 
problems in arsenic case can be examined in detail and solved, these should contribute to a 
better risk assessment methodology needed for regulatory decisions.  More specifically, if we 
had good methods of probabilistic risk assessment better dealing with variability and 
uncertainty issues, we could develop regulatory limits on a contaminant concentration that 
adequately protect human health with an ample margin of safety at a more reasonable cost 
than currently is the case.  Details regarding the issue of arsenic in drinking water will be 
addressed in the following sections. 
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 2.2. Studies on Arsenic and its Health Effects 
 
2.2.1. Source, Fate and Transport of Arsenic 
Arsenic and its compounds are mobile in the environment.  Water is the primary 
medium for arsenic transport in the environment (Pontius et al., 1994).  The pentavalent 
species (As5+, arsenate) is the predominant compound; trivalent arsenic (As3+, arsenite) is 
only found under anaerobic conditions (NRC, 1999).  The cycling of arsenic in the 
environment is presented in Figure 2-4 (USEPA, 2000). 
 
 
Figure 2-4. Environmental Cycling of Arsenic (USEPA, 2000). 
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 Although arsenic is released to the environment from both natural and anthropogenic 
sources, most arsenic is naturally occurring in the environment in both inorganic and organic 
forms.  The major natural source of arsenic is from the erosion, dissolution or weathering of 
arsenic-containing minerals, rocks or soils; the dissolved arsenic enters groundwater or 
surface water.  Other natural sources include volcanic eruption and forest fires.  
Anthropogenic sources are from industrial processes, such as mining, smelting, wood 
preserving, pesticide spraying and coal burning (USEPA, 2000). 
 
2.2.2. Exposure Routes 
Humans are exposed to various forms of arsenic with different toxicities.  The 
metallic form of arsenic (0 valence) has not been shown to be associated with any adverse 
effects; a volatile compound such as arsine (AsH3) is toxic, but is not contained in water or 
food; organic forms of arsenic (primary arsenobetaine and arsenocholine), which can be 
found in fish and shellfish, have little or no toxicity; inorganic arsenic, i.e. arsenite (As3+) and 
arsenate (As5+), are the most prevalent toxic forms found in drinking water, and have been 
reported to be more toxic than the organic ones.  Moreover, the trivalent form (+3) is more 
toxic than the pentavalent one (+5)  (USEPA, 2001). 
Inhalation of air, food intake and ingestion of water are the major routes for humans 
to be exposed to arsenic.  Among these routes, drinking water and food are the most 
significant ones; only a relatively small amount of arsenic is inhaled.  Other routes, such as 
absorption of arsenic through the skin or ingestion of arsenic-containing soils or dust are 
possible but thought to be insignificant (Pontius et al., 1994; Abernathy et al., 1996; 
Abernathy et al., 2003). 
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 Occupational exposure is the major cause of arsenic inhalation, such as workers who 
manufacture arsenical pesticides or work in mines and copper smelters (Frumkin and Thun, 
2001).  Besides occupational inhalation, air mostly represents a minor source of exposure for 
the general population (Buchet and Lison, 2000). 
As for non-occupational exposure, drinking water and food are the major sources 
(Borum and Abernathy, 1994).  Dietary intake is a significant source of arsenic.  Food such 
as seafood, fruits and vegetables contain organic arsenic.  About half of the dietary intakes 
come from seafood, such as fish and shellfish, followed by meat and poultry, grain and grain 
products, and vegetables.  Infants and toddlers also get arsenic through their diet from milk 
and milk products.    However, most adverse health effects of arsenic are from drinking water 
rather than food, because most food arsenicals are organic.  Organic arsenic in food is less 
toxic than inorganic forms and most can be excreted rapidly (Pontius et al., 1994; Abernathy 
et al., 2003).  But the dietary contribution to daily intake of arsenic may become dominant if 
arsenic intake through drinking water is at low concentrations (Hering, 1996). 
Ingestion of arsenic through drinking water is the major concern of arsenic exposure.  
Arsenic concentration is generally higher in groundwater than in surface water, especially 
high in places where geochemical conditions favor arsenic dissolution (Pontius et al., 1994).  
Table 2-1 lists the global arsenic contamination in ground water (Nordstrom, 2002).  And the 
following regions have been found to be geological strata naturally rich in arsenic: Taiwan, 
West Bengal, Mexico, Chile, Argentina, Mongolia, Finland, Hungary and the western and 
southwestern states and Alaska of the US (Chappell et al., 1997; Thornton and Farago, 1997).  
In these regions, the natural arsenic concentration may reach levels up to several hundreds of 
µg/L or even a few mg/L (Buchet and Lison, 2000).  About 98% of the U.S. population uses 
 
18  
 drinking water with concentrations less than 10 µg/L.  But some portion of the remaining 2% 
of the population is exposed to arsenic concentrations that may reach 50-100 µg/L (Chappell 
et al., 1997). 
 
Table 2-1. Global Arsenic Contamination in Ground Water (Nordstrom, 2002) 
Country/Region 
Potential 
Exposed 
Population 
Concentration 
(µg/liter) Environmental Conditions 
Bangladesh 30,000,000 <1 to 2,500 Natural; alluvial/deltaic sediments with high phosphate, organics 
West Bengal, 
India 6,000,000 <10 to 3,200 Similar to Bangladesh 
Vietnam >1,000,000 1 to 3,050 Natural; alluvial sediments 
Thailand 15,000 1 to >5,000 Anthropogenic; mining and dredged alluvium 
Taiwan 100,000 to 200,000 10 to 1,820 Natural; coastal zones, black shales 
Inner Mongolia 100,000 to 600,000 <1 to 2,400 
Natural; alluvial and lake sediments; 
high alkalinity 
Xinjiang, Shanxi >500 40 to 750 Natural; alluvial sediments 
Argentina 2,000,000 >1 to 9,900 Natural; loess and volcanic rocks, thermal springs; high alkalinity 
Chile 400,000 100 to 1,000 
Natural and anthropogenic volcanogenic 
sediments; closed basin; lakes, thermal 
springs, mining 
Bolivia 50,000 - Natural; similar to Chile and parts of Argentina 
Brazil - 0.4 to 350 Gold mining 
Mexico 400,000 8 to 620 Natural and anthropogenic; volcanic sediments, mining 
Germany - <10 to 150 Natural: mineralized sandstone 
Hungary, 
Romania 400,000 <2 to 176 Natural; alluvial sediments; organics 
Spain >50,000 <1 to 100 Natural; alluvial sediments 
Greece 150,000 - Natural and anthropogenic; thermal springs and mining 
United Kingdom - <1 to 80 Mining; southwest England 
Ghana <100,000 <1 to 175 Anthropogenic and natural; gold mining 
USA and 
Canada - <1 to >100,000
Natural and anthropogenic; mining, 
pesticides, As2O3 stockpiles, thermal 
springs, alluvial, closed basin lakes, 
various rocks 
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 2.2.3. Health Effects 
As mentioned previously, inorganic arsenic is considered to be significantly more 
toxic than the organic form.  Thus exposure to organic arsenic is usually not considered in 
assessing health risks (Hering, 1996).  Inorganic arsenic (hereafter called arsenic) in drinking 
water can exert toxic effects after acute (short-term) or chronic (long-term) exposures (NRC, 
1999).  The health effects caused by arsenic are positively correlated with the dose and 
duration of exposure (NRC, 2001), and are classified in Table 2-2. 
 
Table 2-2. Health Effects of Arsenic 
Health Effects Symptoms References 
Acute toxicity 
Gastrointestinal irritation accompanied by difficulty 
in swallowing, thirst, abnormally low blood 
pressure, and convulsions. 
Death because of cardiovascular collapse. 
(Pontius et al., 
1994) 
Chronic non-
cancerous effects 
Dermal changes, such as skin pigments, 
hyperkeratosis, and ulcerations. 
Vascular effects, such as blackfoot disease 
Cardiovascular, pulmonary, immunological, 
neurological and endocrine (e.g., diabetes) effects. 
(Pontius et al., 
1994) 
 
(NRC, 1999) 
Chronic cancerous 
effects 
Skin cancer 
Internal cancers, such as bladder, lung, and liver 
cancer.   The evidences for other cancers, such as 
kidney, nasal passages, prostate, and other internal 
sites cancer are not strong. 
(NRC, 1999) 
 
2.2.3.1. Cancerous Effects 
Ingestion of inorganic arsenic may have chronic cancerous effects.  The 1999 NRC 
report confirmed that arsenic in drinking water causes bladder, lung and skin cancer, and 
might cause kidney and liver cancer.  Skin cancer has been established as a health effect.  
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 However, skin cancer is not as great a concern as other internal cancers because internal 
cancers are life threatening but most skin cancers are not (NRC, 2001). 
The evidence for lung and urinary bladder cancers has been strengthened by recent 
studies in Taiwan, Argentina, and Chile.  But most of these epidemiological studies for 
cancer were from areas with relatively high arsenic concentration (at least several hundred 
micrograms per liter, which is much higher than the average concentration in the U.S.).  
Cancer risk at lower concentrations of ingested arsenic, however, has been seldom addressed 
in such studies.  Other cancers, such as kidney and liver cancer, have also been found to have 
an association with ingestion of inorganic arsenic.  Nevertheless, their association is not 
strong enough to allow reliable identification of increased risk in existing studies.  Therefore, 
further confirmatory studies are needed to establish arsenic as a cause of cancers other than 
skin, lung and bladder cancers (NRC, 1999). 
 
2.2.3.2. Non-cancerous Effects 
Ingestion of inorganic arsenic may also have chronic non-cancerous effects on 
multiple-organ systems.  These effects are dependent on the magnitude of the dose and the 
time course of exposure.  The toxicokinetic and toxicodynamic interaction between the dose 
and exposure time has still not been well characterized.  From the available data, some 
general findings have emerged, such as hypertension and diabetes, although the NRC found 
the relationship still unquantifiable.  Effects noted by the NRC include (NRC, 1999): 
(1) Nonmalignant dermal effects, such as diffuse or spotted hyperpigmentation and palmar-
plantar hyperkeratoses. 
(2) Obvious nonspecific gastrointestinal complaints, such as diarrhea or cramping. 
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 (3) Hematological effects, such as anemia and leukopenia. 
(4) Neurological effects, such as a sensory predominant axonal peripheral neuropathy. 
(5) Cardiovascular effects, such as irreversible noncirrhotic portal hypertension and 
cardiovascular mortality. 
(6) Peripheral vascular disease, such as Blackfoot disease. 
(7) Cerebrovascular disease, but the evidence for this effect is not clear. 
(8) Diabetes (diabetes mellitus). 
(9) Immune function effects, but these effects have not been adequately studied in field 
research. 
(10) Respiratory effects, but the specific pathology of this effect has not been investigated. 
(11) Reproductive and development effects.  Arsenic may be teratogen and can cause 
stillbirth, increase of infant mortality, preterm births, or spontaneous abortions. 
 
2.3.3.3. Blackfoot Disease in Taiwan 
Blackfoot disease is a peripheral vascular disease and has been endemic in a small 
area on the southwest coast of Taiwan since 1954.  Disease symptoms start with spotted 
discoloration of the skin of extremities, especially the foot.  The spots change from white to 
brown, then to black.  Affected skin gradually thickens, cracks, and ulcerates (Tseng et al., 
1968).  A considerable percentage of patients suffered from great pain and even tried to 
commit suicide because the pain was intolerable.  Some of them finally had to cut their 
affected extremities.  This has caused much inconvenience and difficulty in daily lives and 
social problems.  It has been found that the prevalence of Blackfoot disease was related to the 
ingestion of water from deep wells with high arsenic concentration. 
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 People who have lived in villages along the southwest coast have used artesian well 
water with high concentration of arsenic since the 1900s.  Artesian well water was no longer 
used during the mid-1970s because the tap-water system had been gradually installed since 
1956.  The government also persuaded residents not to drink arsenic-containing well water or 
groundwater.  As time went by, the Blackfoot disease cases decreased gradually and were 
almost eliminated.  However, 40 years later in 1996, about 20 people got a similar disease in 
the northeast area of Taiwan.  The groundwater in this area also contains high concentrations 
of arsenic (Chiou et al., 2001).  The fact that Blackfoot disease was prevalent in the areas 
with high arsenic concentration in groundwater has been noted, and substantial studies have 
been done in Taiwan. 
 
2.2.4. Epidemiological Studies of Arsenic Exposure and Cancer Risk 
Inorganic arsenic is not typically found to cause tumors in standard laboratory animal 
tests, while the observational studies of human exposures to arsenic through ingestion have 
been strongly associated with increases in skin and internal cancers (Clewell et al., 1999).  
Still, the association between arsenic exposure and cancerous effects is controversial and not 
well established in the epidemiological field.  Varied or even opposite results have been 
found in different epidemiological studies of different regions.  Some studies (e.g. studies in 
Taiwan) showed significantly elevated incidence or mortality of cancers for the population 
exposed to arsenic, while some others (e.g. studies in the US) failed to show an association 
between arsenic in drinking and the adverse health effects. 
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 2.2.4.1. Epidemiological Studies in Taiwan 
Since 1968, researchers in Taiwan kept finding that populations in these Blackfoot-
endemic areas also had high rates of some cancers, such as skin, bladder, kidney, liver, and 
lung cancer (Tseng et al., 1968; Tseng, 1977; Chen et al., 1985; Chen et al., 1988; Wu et al., 
1989; Chen and Wang, 1990; Chen et al., 1995; Chen et al., 1996; Chiou et al., 1997; Hsu et 
al., 1997; Hsueh et al., 1997; Tsai et al., 1998; Tsai et al., 1999).  Most of these 
epidemiological studies showed that there was a significantly elevated incidence of cancers 
for the study population (which is confined in the Blackfoot disease endemic area) compared 
with lesser-exposed populations in both communities with similar socio-economic structure 
as well as with the general population in Taiwan.  Some studies also showed dose-response 
relationships with increasing arsenic concentrations (NRC, 1999).  Chappell et al. (1997) 
remarked on the possible shortcomings of these studies, noting that “these studies from 
Taiwan demonstrate a dose-response relationship for cancer at various sites and arsenic 
concentrations in water, but the data are not sufficiently precise for accurate quantitative 
assessment of the magnitude of cancer risk at different arsenic concentrations needed to set 
an MCL in the United States because the studies report exposures for groups of people rather 
than for individuals” (Chappell et al., 1997). 
The two prevalence studies of skin cancer conducted by Tseng and his colleagues 
(Tseng et al., 1968; Tseng, 1977) were recognized as the best available data for EPA to 
conduct quantitative risk assessment (USEPA, 1984; USEPA, 1988).  However, the 
shortcomings of these studies are that the exposure categories are too broad and too few:  
There were only three defined exposure categories (0-290 µg/L, 300-590 µg/L, 600 µg/L and 
above, and undetermined) and the upper limit of the lowest exposure category was quite high 
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 (290µg/L).  Another shortcoming is that these studies were ecological in design and the data 
were analyzed by using all residents in a given village instead of an individual as a unit (Guo 
and Valberg, 1997).  Chen and his colleagues did another important epidemiological study 
(Chen et al., 1985; Chen et al., 1988).  They studied the same regions as Tseng et al. did, but 
used mortality data.  They found an increased occurrence of cancer in internal organs, 
including bladder, liver, lung and other sites.  Their studies had similar shortcomings with the 
ones of Tseng el al. with respect to exposure grouping and ecological study design.  U.S. 
EPA (USEPA, 1988) used the Tseng study data to conduct a dose-response assessment for 
skin cancer, while Smith el al. (Smith et al., 1992) used the Chen study data to conduct a 
dose-response assessment for internal cancers (bladder, liver, lung, kidney)  (Brown et al., 
1997). 
While most of the previous Taiwanese studies were conducted in an area with 
relatively high arsenic concentration (200 ppb or more), recent studies have discovered that 
low-dose exposure to arsenic may also increase the risk of certain types of cancer, diabetes 
and vascular disease.  This study conducted by Chiou et al (2001) examined cases of urinary 
tract cancer in villagers exposed to arsenic levels as low as 10 to 50 ppb.  His research 
concluded that there was a significantly increased incidence of urinary cancers for the study 
cohort compared with the general population in Taiwan, even at low arsenic concentration.  
This study had a better study design that estimated arsenic exposure at an individual level 
(i.e., based on the arsenic concentration in his or her own well water), making the study result 
more reliable (Chiou et al., 2001).  Also, this study and the one done in Chile (Ferreccio et al., 
2000) were said to “have adequate data to contribute to quantitative assessment of risk” in 
NRC’s arsenic report in 2001 (NRC, 2001). 
 
25  
 2.2.4.2. Epidemiological Studies of Arsenic in the U.S. 
Despite there being substantial studies outside the U.S., it is still unclear whether 
arsenic in drinking water occurring at environmental levels leads to adverse health effects in 
the U.S. 
Early US studies (Goldsmith et al., 1972; Morton et al., 1976; Harrington et al., 1978; 
Southwick et al., 1983; Valentine et al., 1985) in communities with high arsenic levels in 
water supplies have failed to show an association between arsenic in drinking water and 
adverse health effects.  However, Bates el al. (1992) pointed out that “these studies have had 
cross-sectional designs, and the exposed populations have been small, probably relatively 
mobile and with access to alternative water sources” (Bates et al., 1992).  These factors 
generated statistical power too low to detect effects (Pontius et al., 1994).  Other 
epidemiological studies (Valberg et al., 1998) showed the same results of health effects in 
high-arsenic regions; i.e. no association between skin-cancer prevalence and arsenic in 
drinking water was found.  This result could be due to an absence of risk in the U.S. 
populations or statistical limitations due to small sample sizes  (Chappell et al., 1997). 
More recently, the Utah Study (Lewis et al., 1999) did not find any excess bladder or 
lung cancer risk with exposure to arsenic at concentrations from 14 to 166 µg/L.  They 
estimated excess risk by comparing cancer rates among the study population, in Millard 
County, Utah to background rates in all of Utah, and the result showed that there are 
important differences between the study and comparison populations besides their 
consumption of arsenic.  One explanation for such a difference is that Millard County is 
mostly rural, while Utah as a whole contains some large urban populations.  Another 
explanation is that the subjects of the Utah study were all members of the Church of Jesus 
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 Christ of Latter Day Saints, who for religious reasons have relatively low rates of tobacco 
and alcohol use.  Therefore, this study was criticized in that “the comparison of the study 
population to all of Utah is not appropriate for estimating excess risks” (USEPA, 2001).  The 
Agency (USEPA, 2000) reanalyzed the Utah data by an alternative method of comparing 
cancer rates only among people within the study population who had high and low exposures.  
The results showed that there was still no detectable increased risk of lung or bladder cancers 
due to arsenic, even among subjects exposed to more than 100 µg/L on average”.  And the 
EPA finally concluded: “The Utah study is not powerful enough to estimate excess risks with 
enough precision to be useful for the Agency’s arsenic risk analysis” (USEPA, 2001). 
Karagas and his colleagues (2001) conducted a case-control study to investigate the 
relationship between skin cancer risk and arsenic exposure in New Hampshire.  They used 
toenail arsenic concentrations as a biological marker of arsenic exposure through drinking 
water. While the risks did not appear elevated at the toenail arsenic concentrations detected 
in most study subjects, the authors could not exclude the possibility of a dose-related increase 
at the highest levels of exposure experienced in the New Hampshire population (Karagas et 
al., 2000; Karagas et al., 2001).  Schoen et al. (2004) summarized epidemiological studies in 
the U.S. in the following Table 3 (Schoen et al., 2004). 
 
2.2.4.3. Epidemiological Studies of Arsenic in Other Areas 
Results of arsenic studies in other areas have been mixed.  An association was found 
between bladder cancer mortality and arsenic in drinking water in Argentina (Hopenhayn-
Rich et al., 1996).  They also found that arsenic ingestion increases the risk of lung and 
kidney cancers, but the association between arsenic and mortality from liver and skin cancers 
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 was not clear in another study (Hopenhayn-Rich et al., 1998).  Another case-control study in 
Argentina done by Bates et al. (2004) found increased bladder cancer risks associated with 
high levels of arsenic in drinking water, but little information exists about risks at lower 
concentrations.  This study suggests lower bladder cancer risks for arsenic than predicted 
from other studies, but the authors add that the latency for arsenic-induced bladder cancers 
may be longer than previously thought (Bates et al., 2004). 
Kurttio et al. (1999) studied the association of arsenic exposure from drilled well 
water with the risk of bladder and kidney cancers in Finland.  In spite of very low exposure 
levels, some evidence of an association between arsenic and bladder cancer risk was found.  
But none of the exposure indicators was statistically significant in the association with the 
risk of kidney cancer (Kurttio et al., 1999). 
Increased mortality in bladder and lung cancers were found in a region of northern 
Chile (Smith et al., 1998).  Ferreccio et al. (2000) conducted a case-control study in cities in 
northern Chile where arsenic concentration was 860 µg/L in drinking water in the period 
1958–1970 and reduced to 40 µg/L since then.  They investigated the relation between lung 
cancer and arsenic in drinking water over time.  Strong evidence has been shown that 
ingestion of inorganic arsenic is associated with lung cancer (Ferreccio et al., 2000).  Due to 
many strengths of this study, the data from this study were evaluated to be useful in further 
quantitative risk assessment (NRC, 2001). 
A complete list and summary of current major epidemiological studies from different 
regions, in which cancers are the end points to be investigated, are presented in NRC reports 
(NRC, 1999; NRC, 2001).  Please see Tables 2-3 for details (Schoen et al., 2004). 
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Table 2-3. Summary of US-based epidemiological studies of cancer risks from exposure to arsenic. 
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 2.3. Cancer Risk Assessment of Arsenic in the U.S. 
 
2.3.1. Existing Risk Assessment for Arsenic 
Cancer risk has been the driving effect in regulatory decisions because non-cancer 
effects are likely to be significant only at concentrations well above the considered MCLs 
(USEPA, 2001).   Therefore, the discussion about arsenic risk assessment in this chapter is 
focused on cancer. 
Most arsenic cancer risk assessments have been based on epidemiological studies.  In 
the United States, the risk assessments of arsenic from drinking water were at first done for 
skin cancer.  And it was agreed that ingested arsenic causes enhanced skin cancer risk.  Then, 
several risk assessments were done for internal organ cancers (lung, liver, kidney, bladder) 
from drinking arsenic-rich water, and it was also shown to cause increased risk in these end 
points.  However, because of uncertainty and variability issues in risk assessment, there have 
been several debates about the validity of these risk assessments. 
 
2.3.1.1. Skin Cancer 
The U.S. EPA (1984, 1988) conducted a risk assessment for skin cancer by using data 
from southwestern Taiwan where Blackfoot disease is endemic (Tseng et al., 1968; Tseng, 
1977).  The EPA used the “cancer slope factor” (CSF) or the “cancer potency factor” as an 
estimation of carcinogenic potency and assumed a linear dose-response relationship (USEPA, 
1988; Brown, 1998).  The upper-bound excess cancer risk from lifetime exposure to water 
containing 1 µg As per liter (unit risk) was calculated to equal to 5 × 10-5 by using a 
generalized multistage model.  Consuming drinking water at the MCL of 50 µg/L (which was 
the MCL of arsenic at that time) entailed a lifetime risk of 2.5 ×10-3.  However, the unit risk 
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 calculated by the EPA could overestimate the actual risk for skin cancer.  That is because the 
EPA extrapolated data from Taiwan with high-level arsenic exposures linearly to generate 
risk estimates for low-level exposures in the U.S.  For this extrapolation, the EPA 
hypothesized that a linear dose-response relationship applies in the low-dose exposure region 
and that carcinogens do not have a threshold.  The appropriateness of these assumptions and 
the validity of the risk assessment evoked significant debate (Chappell et al., 1997; Guo and 
Valberg, 1997; Clewell et al., 1999).  Guo et al. (1997) did a quantitative review of 
epidemiological studies observing arsenic exposure below 290 µg/L, which is the lowest 
exposure category in the Taiwan study used by the EPA.  Their review suggested, “The EPA 
model is unlikely to be able to predict the risk of skin cancer accurately when the arsenic 
exposure level is between 170 and 270 µg/L” (Guo and Valberg, 1997).  Subsequently, using 
data from four epidemiological studies in the U.S. (Harrington et al., 1978; Southwick et al., 
1983; Vig et al., 1984) and the EPA cancer slope factor (CSF) for ingested arsenic, Valberg 
et al. (1998) calculated the incidence of skin cancer in the U.S. population.  Then, they 
conducted a likelihood ratio analysis to test the null hypothesis that there were no extra skin 
cancer cases caused by arsenic (i.e. no risk) versus the alternative hypothesis of a predicted 
risk, which was not apparent due to random variability.  Their result showed that a null 
hypothesis was approximately 2.2 times more likely than the alternative hypothesis, favoring 
the hypothesis of no additional skin cancer risk from arsenic.  Although several sources of 
uncertainty in the U.S. data, such as exposure duration and misclassification, affected their 
predictions of skin cancer prevalence, the authors suggested “the CSF derived by EPA from 
the Taiwanese population may be an overestimate of the skin cancer risk in the U.S. (Valberg 
et al., 1998).”  Many other questions had been raised about EPA’s risk assessment, including 
 
32  
 applicability of the risk assessment to the U.S. population, the role of arsenic as an essential 
nutrient, the relevance of skin lesions as the basis for the risk assessment, and the role of 
arsenic intake via food  (Morales et al., 2000). 
Brown et al. (1989) also conducted a risk assessment for skin cancer from ingesting 
inorganic arsenic based on the study of Tseng et al (1968).  The derived lifetime risks of 
developing skin cancer are 3.0×10-3 (2.1×10-3) for U.S. males (females) if exposed to 1 
µg/kg/day for a 76-year lifespan using the linear model, and are 1.3×10-3 (6.0×10-4) for U.S. 
males (females) using the quadratic model.  The authors pointed out that this study might 
overestimate the skin cancer risk from ingested arsenic since other sources were not 
considered.  On the contrary, this study might underestimate the risk since people dying from 
gangrene and skin cancer were not counted in the prevalence study of Tseng et al. (1968).  
Different diet habits between the Taiwanese and U.S. populations are another source of 
uncertainty (Brown et al., 1989). 
 
2.3.1.2. Internal Cancers 
Smith et al. (1992) conducted a risk assessment for cancer risks of liver, lung, kidney 
and bladder associated with inorganic arsenic in drinking water.  They established the dose-
response relationship for the U.S. population by linear extrapolation using Taiwan data from 
the epidemiological studies of Chen et al. (1988) and Wu et al. (1989).  The results of their 
study showed that at an MCL of 50 µg/L, the lifetime risk of dying from these internal 
cancers from drinking 1 L/day of water could reach to 13 per 1000 persons (1.3×10-2); when 
considering the average arsenic levels and water consumption patterns in the U.S. population, 
the population-averaged risk estimate was around 10-3 (Smith et al., 1992).  This study had 
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 drawn attention to the potential for internal cancer risks in the U.S., but its uncertainty has 
also been noted (Pontius et al., 1994).  Carlson-Lynch et al. (1994) commented that some 
flaws in the study of Smith et al. may lead to an approximately 10 fold higher CSF (18 per 
mg/kg-day) than the current CSF in IRIS (1.75 per mg/kg-day).   One flaw was that the linear 
regression contained the assumption that the arsenic intake of the control population was zero.  
This unrealistic assumption might artificially increase the slope factor.  Other flaws included 
the uncertainties in the use of Taiwanese data, the possible correlation of humic acids, and 
different diets and protein intake between Taiwanese and U.S. populations (Carlson-Lynch et 
al., 1994). 
Chen et al. (1992) calculated cancer potency indices of the lung, liver, bladder and 
kidney based on the mortality data (Chen et al., 1985; Chen et al., 1986; Chen et al., 1988) of 
residents in the Blackfoot-endemic areas in southwestern Taiwan by using the Armitage-Doll 
multistage model.  The excess lifetime risk of developing liver, lung, bladder and kidney 
cancers due to an intake of 1 µg/kg/day of arsenic was estimated as 4.3×10-4, 1.2×10-3, 
1.2 10× -3, and 4.2×10-4, respectively, for males; as well as 3.6×10-4, 1.3×10-3, 1.7×10-3, and 
4.8 10× -4, respectively, for females in study area (Chen et al., 1992). 
Brown and Chen (1995) used the Taiwanese data (Chen et al., 1985) for dose-
response assessment.  Identifying some problems in the raw data, the authors deleted some 
outliers and adjusted some exposure values.  They found “for all endpoints and both genders, 
an upturn in response begins in the region where arsenic concentration is above 100 µg/L”, 
but the resultant dose-response patterns showed no evidence of excess risk below arsenic 
concentrations of 100 µg/L.  Moreover, the dose-response relationships between internal 
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 cancers (bladder, liver, and lung) prevalence and arsenic exposure was nonlinear (Brown and 
Chen, 1995). 
At the request of the EPA to independently review the scientific database and 
evaluate the scientific validity of its 1988 risk assessment, the National Academy of 
Science’s National Research Council (NRC) presented a more detailed summary of the 
evidence linking arsenic exposure to internal cancer in its report “Arsenic in Drinking Water” 
in 1999.  NCR also made several recommendations for the risk assessment of arsenic from 
drinking water in this report (NRC, 1999): 
(1) To improve the scientific validity of arsenic risk assessment, additional epidemiological 
evaluations are needed to characterize the does-response relationship, especially at low doses. 
(2) Since the mechanism (or mode of action) by which inorganic arsenic causes cancer is not 
well established, biologically based models (chronic studies in a suitable animal model) at 
low-dose might increase this understanding. 
(3) Due to the variation in human sensitivity to the toxic effects of inorganic arsenic 
exposure, factors that influence sensitivity to or expression of arsenic-associated cancer 
effects need to be better characterized.  The possible factors are genetics, gender, metabolism, 
diet, health status, and nutritional status.  
(4) More data are needed that tie biomarkers of absorbed arsenic dose to arsenic exposure 
concentration, especially in different parts of the U.S. 
In the absence of a well-designed and well-conducted epidemiological study that 
includes individual exposure assessments, NRC (1999) concluded, “Ecological studies from 
the arsenic endemic area of Taiwan provide the best available empirical human data”.  After 
characterizing risks at an MCL of 50 µg/L “based on observed epidemiological findings, 
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 experimental data on the mode of action of arsenic, and available information on the 
variations in human susceptibility”, the NRC (1999) concluded that risk at an MCL of 50 
µg/L was still too high to achieve EPA’s goal for public-health protection. 
The EPA also released details of a regulatory risk assessment for arsenic in drinking 
water, and the basis for a decision on a proposed rule for arsenic and its MCL through the 
Federal Register in June 2000 and January 2001 (USEPA, 2001).  These reports utilized 
slightly revised unit risk factors developed by the NRC (NRC, 1999) to estimate risks from 
arsenic exposure through drinking water.  Specifically, the unit risk factor was approximately 
2.6×10-5 per µg/L in the EPA assessment and 2×10-5 per µg/L in the NRC assessment. 
Morales et al. (2000) produced a risk assessment for cancers of the bladder, liver, and 
lung from exposure to arsenic in water, based on a set of epidemiological data from an 
arseniasis-endemic region of Taiwan (Chen et al., 1985; Chen et al., 1988; Wu et al., 1989; 
Chen et al., 1992).  The excess lifetime risk was estimated by considering several variations 
of models and alternative methods for incorporating background rates into the analysis.  
Their results agreed with the conclusion of the NRC (1999) that “The standard of 50 µg/L at 
that time is associated with a substantial increased risk of cancer and is not sufficiently 
protective of public health”.  The authors also argued that they did a better risk assessment 
than that of the EPA for the following reasons (Morales et al., 2000): 
(1) Their study focused on mortality from bladder, lung, and liver cancers identified through 
national death records. 
(2) In the EPA analysis, they grouped data (Tseng et al., 1968) into three broad exposure 
intervals [low (< 300 µg/L), medium (300-600 µg/L), and high (> 600 µg/L)].  But data 
used by Morales et al. (2000) provided exposure at the individual village level. 
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 In another report of “Arsenic in Drinking Water: 2001 Update”, the NRC (2001) 
concluded: “Arsenic-induced internal (lung and bladder) cancers should be the principal 
focus of arsenic risk assessment for regulatory decision-making”.  They used the additive 
Poisson model as the statistical fit for human data from southwestern Taiwan.  Their 
estimates of mean theoretical lifetime excess risk of lung cancer and bladder cancer for U.S. 
populations at different MCLs of concern in drinking water are shown in Table 2-4 (NRC, 
2001). 
 
Table 2-4. Theoretical Lifetime Excess Risk (Incidence per 10,000 People) of Lung 
Cancer and Bladder Cancer for U.S. Populations at Different MCLs in Drinking Water. 
 
Table Source: (NRC, 2001) 
 
2.3.2. Variability Issues in Arsenic Risk Assessment 
There exist variability and uncertainty issues in risk assessment for science-based 
environmental policy.  Variability comes from differences in outcome due to inter-subject 
variation in factors contributing to risk; uncertainty comes from lack of knowledge in the 
underlying science.  The purpose of studying variability and uncertainty is to make sure a 
reasonable fraction of the population is protected with an ample margin of safety and 
confidence. 
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 Human sensitivity or susceptibility to adverse health effects of arsenic exposure is 
likely to vary because of genetics, metabolism, diet, health status, nutrition, sex, and other 
possible factors.  These factors can have important impacts on arsenic risk.  For example, 
poor nutrition and arsenic intake from food might affect the epidemiological results in 
Taiwan or the results of extrapolation to the United States (NRC, 1999). 
Existing risk assessments, however, do not fully quantify the risks to sensitive and 
susceptible subpopulations, but only reflect the average risk in a population.  The possible 
sensitive subpopulations include people with poor nutritional status, infants or children, 
pregnant and lactating women.  Generally speaking, they are more susceptible because of 
variations in metabolism and sensitivity among individuals or groups.  For example, they 
may have reduced ability to methylate arsenic, and therefore retain more arsenic in their 
bodies, placing them at greater risk for toxic effects (NRC, 1999).  Infants and children might 
be especially susceptible because their tissue dose of arsenic might be, on average, higher 
than that of adults exposed to similar waterborne concentration due to their higher fluid and 
food intake on a body-weight basis (NRC, 2001).  Also, studies in northern Argentina 
showed that children might have lower arsenic-methylation efficiency than adults (Concha et 
al., 1998; Concha et al., 1998).  As for pregnant and lactating women, there are no reliable 
data that indicate increased susceptibility to arsenic.  But they might be especially important 
to consider as a separable subpopulation due to possible adverse reproductive and 
developmental effects of arsenic (USEPA, 2000).  People with poor nutritional status might 
have decreased ability to methylate arsenic, resulting in increased arsenic concentrations in 
tissues and the development of toxic effects (NRC, 1999).  Because these individuals or 
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 subpopulations may have higher risks than the general population, a wider margin of safety 
might be needed when selecting risk management options for arsenic. 
 
2.3.3. Uncertainty Issues in Arsenic Risk Assessment 
The following three are the factors that are most often addressed in the literature on 
uncertainty as it relates to arsenic risks: (1) model choice in the dose-response relationships; 
(2) data limitations; and (3) other sources of exposure, such as dietary intake.  Brown et al. 
(1997) also pointed out four sources of uncertainty in calculating the magnitude of risk at low 
concentrations of arsenic: model choice, data aggregation, intra-village variability of arsenic 
in well water, and arsenic intake from food (Brown et al., 1997).  Only the issues of model 
choice and data limitations are addressed here since they relate to the topic of the proposed 
research. 
 
2.3.3.1. Model Choice in the Dose-Response Relationship 
In the case of arsenic risk, several primary sources of uncertainty make the choice of 
dose-response model controversial: lack of good animal models from experimentation; 
inaccurate dose-response models due to inadequate epidemiological data; and incomplete 
knowledge of the uptake, bio-transformation, and distribution of arsenic in the body 
(Chappell et al., 1997). 
The shape of the dose-response relationship between health risks and arsenic 
exposure from drinking water may be based on experimental animal data or epidemiological 
data (Wright et al., 1997).  Present experiments in animals are thought to be not appropriate 
for use in the quantitative human health risk assessment for arsenic, while many extensive 
 
39  
 human epidemiological studies of arsenic exposure and cancer risk are available.  However, 
very limited epidemiological data in the U.S. are available to assess the dose-response 
relationship (Guo and Valberg, 1997).  Therefore, researchers and policy-makers in the U.S. 
mostly used the studies of cancer in Taiwanese villagers exposed to arsenic from wells from 
the 1920s to 1960s as the primary body of data to develop their risk estimates (NRC, 1999).  
Taiwan is currently the place with the most complete data because Blackfoot disease has 
been endemic in southwestern regions.  However, those arsenic data from Taiwan were 
obtained at relatively high concentrations of 200 µg/L or more.  To estimate risks at levels 
below 50 µg/L, experts have used the default linear assumption to extrapolate the data.  But 
if there is a threshold, i.e. a level of exposure below which arsenic-laced water is harmless, or 
if the dose-response relationship is non-linear, that modeling technique could overestimate 
the risk.   Also, with other factors such as different genetics, diet and health status between 
the U.S. and Taiwan populations, there are doubts as to whether it is reasonable to simply 
extrapolate the data across populations.  Therefore, there are issues with the extrapolation of 
the dose-response relationship from the observed range of exposures in Taiwan to estimate 
U.S. cancer risk below the observed data range. 
Traditionally, EPA has used the default assumption that “risk is linearly related to 
dose and that any dose, no matter how small, poses some level of risk” (Clewell et al., 1999).  
The EPA used the “cancer slope factor” (CSF) or the “cancer potency factor”, which assumes 
a linear dose-response relationship for cancer, as an estimation of carcinogenic potency for 
arsenic (USEPA, 1988; Brown, 1998).  However, Brown (1998) argued, ‘This “EPA 
approach” is poorly suited to the available information and data on arsenic’ (Brown, 1998).  
Also, there is other evidence from pharmacokinetic studies indicating either a threshold for 
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 the carcinogenic effects of arsenic or a sub-linear dose-response relationship at low doses of 
arsenic.  In addition, it is found that “in humans, inorganic arsenic can be metabolized into 
less toxic organic forms”.  This mechanism may be more effective at low doses, and thus it 
may be reasonable to assume the dose-response curve is not linear in the low-dose region 
(Carlson-Lynch et al., 1994; Guo and Valberg, 1997).  Moreover, “an indirect effect of 
arsenic on DNA repair is consistent with the expectation of a nonlinear dose-response rather 
than the linear dose-response traditionally assumed for mutagenic carcinogens”.  Clewell et 
al. (1999) proposed that to improve the current cancer risk assessment for arsenic would 
require: (1) the development of clearly articulated hypotheses of the mode-of-action of 
arsenic as a human carcinogen, (2) specific experimentation in appropriate animal species to 
bolster the evidence for the proposed mechanisms and to rule out competing mechanisms, 
and (3) a quantitative risk model to integrate pharmacokinetic and mechanistic experimental 
results and provide expectations of the low-dose risk consistent with the proposed 
mechanism (Clewell et al., 1999). 
In a word, the uncertainty of model choice in the dose-response analysis of arsenic is 
due to the lack of knowledge of arsenic pharmacokinetics and pharmacodynamic 
mechanisms in humans, and the inconsistency of current epidemiological evidence (Pontius 
et al., 1994).  While the traditional default linear assumption has been used in regulatory risk 
assessments to date, a threshold for arsenic carcinogenicity or a non-linear dose-response 
relationship at low doses may be the case (Clewell et al., 1999). 
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 2.3.3.2. Data Limitations 
There are several advantages to the database from Taiwan (USEPA, 2001): 
? Mortality data were drawn from a cancer registry; 
? Arsenic well water concentrations were measured for each of the 42 villages; 
? There was a large, relatively stable study population that had life-time exposures to 
arsenic; 
? There are limited measured data for the food intake of arsenic in this population; 
? Age- and dose-dependent responses with respect to arsenic in the drinking water were 
demonstrated; 
? The collection of pathology data was unusually through; 
? The population was quite homogeneous in terms of lifestyle. 
However, the EPA (2001) also recognized that there are some problems with the 
Taiwan studies that introduce uncertainties into the risk analysis, such as: 
? The Taiwan data on exposure were uncertain due to use of median exposure data at the 
village level and the possible errors in assigning persons to exposure.  The researchers 
investigated the association of individuals with contaminated wells by assigning all 
villagers to a single median arsenic concentration for exposure and assuming they all had 
a lifetime of exposure to the wells serving that village.  However, wells within each 
village had varying arsenic levels so that people also had varying exposure to arsenic 
concentration according to the real wells they used.  The median concentration was also 
questionable since not all wells serving all villages were measured.  In addition, moves 
made from village to village were not accounted for. 
? Most available studies from Taiwan are ecological studies. 
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 ? Confounding factors that may have contributed to risk may not be adequately accounted 
for. 
? There were many differences between the Taiwan and U.S. populations, such as genetics, 
lifestyles, nutrition status, making the use of Taiwanese data for the U.S. population 
doubtful.  The Taiwanese study population was a rural population, mostly low income, 
relatively poorly nourished and having deficits of selenium, possibly methionine or 
choline (methyl donors), zinc and other essential nutrients.  Deficits (particularly in 
selenium) in the diet may be a risk factor for cancer.  Since this malnourishment is not 
typical of the U.S. population, risk may be overestimated when the Taiwan data are 
applied.  The Taiwanese population may also have some genetic differences from the 
general U.S. population. However, these issues cannot be quantitatively accounted for. 
? There was high exposure of the Taiwan population to arsenic via contaminated food and 
cooking water.  This is because the staples of the Taiwan diet were rice and sweet 
potatoes.  Rice and sweet potatoes are high in arsenic and both staples absorb water upon 
cooking. 
The first three problems, which involve the flaws in original data collection and 
research design in epidemiology, contribute a lot to uncertainty in the quantitative dose-
response analysis.  Other problems, such as possible dietary deficiencies and intake of 
arsenic from other sources, may contribute little uncertainty.  This is because studies of skin 
and possible internal cancers from arsenic in drinking water have been done in many 
different countries, where the diet and many other factors vary, and the additional 
information in these factors seems unlikely to change the dose-response curve greatly 
(Abernathy et al., 1996). 
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 2.3.4. Conclusion 
The risk assessment of arsenic in drinking water has been mostly based on the 
epidemiological studies.  The unit risks1 calculated by different risk assessors are ranged 
around 10-5 (per µg/L) for internal cancers.  However, several variability and uncertainty 
issues make cancer risk assessment controversial for arsenic.  This research focuses on these 
two issues to improve the risk assessment methodology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 The unit risk is the quantitative estimate in terms of either risk per µg/L drinking 
water taken. 
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 CHAPTER 3 METHODOLOGIES AND RESULTS 
 
Four methodologies have been developed in this study.  They are (i) Using meta-
analysis in dose-response assessment; (ii) Quantification of margin of safety; (iii) The 
alternate method of quantification of margin of safety with meta-analysis results; and (iv) 
Price of confidence.  Figure 3-1 is the influence diagram shown the steps of these 
methodologies, and they are introduced separately in the following sections. 
 
Figure 3-1. The influence diagram of steps of methodologies (in blue color). 
 
 3.1. Using Meta-Analysis in Dose-Response Assessment 
 
3.1.1. Introduction of Meta-Analysis of Observational Studies 
The dose-response assessment usually proceeds in two steps.  The first step is the 
assessment of the data in the range of empirical observation, followed by the step of 
extrapolation to lower dose levels, if needed (USEPA, 2003).  This methodology focuses on 
the first step by applying meta-analysis. 
In risk-based regulation, data are needed to characterize the dose-response 
relationship for risk calculations.  The accuracy of the data and the ability to fit them by an 
appropriate model in turn determine the scientific validity of a risk assessment (NRC, 1999).  
Usually, human data are scant and animal data are used.  But in the case of arsenic risk 
assessment, there are inadequate data and models from animal experiments, while there are 
relatively plentiful human data from observational studies 2  (Abernathy et al., 1996).  
Therefore, arsenic cancer risk assessments have been mostly based on observational studies 
in epidemiology. 
There are many advantages to using epidemiological studies as a source of data for 
dose-response analysis in risk assessment, including development of direct evidence of 
carcinogenic or other health effects in humans, thereby avoiding the uncertainty associated 
with inter-species extrapolation.  However, current epidemiological evidence is highly 
                                                 
2 Observational studies and clinical trials are two main types of research design in 
epidemiology.  Different from clinical trials, which are relative consistency of study 
designs and similarity of outcome measures, group of subjects cannot be randomly 
assigned to one or another exposure group in observational studies.  This is why meta-
analysis has been facilitated in the area of clinical trials but still have controversial in 
the area of observational studies (Morris, 1994; Stroup, et al., 2000) 
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 variable and at times conflicting.  So it is not appropriate to draw a firm conclusion about the 
shape or magnitude of the dose-response relationship based on an individual study. 
Meta-analysis is a statistical tool for integrating and analyzing data from related but 
independent studies.  Applying a set of statistical procedures, which quantitatively aggregate 
the results of multiple primary studies, an overall conclusion or summary of average 
properties such as risk coefficients across these studies may be reached (Arthur et al., 2001).  
If conducted appropriately, the overall conclusion or summary measure could be a more 
objective appraisal of the evidence, and uncertainty and disagreement among studies can also 
be characterized (Egger and Smith, 1997).  Moreover, meta-analysis assists in the exploration 
and evaluation of results, including the heterogeneity between results of individual studies 
and among subgroups, such as genders, ages, or ethnic groups.  This additional information 
helps in characterizing uncertainty and locating sources of inter-subject variability (Egger 
and Smith, 1997). 
The quantitatively-aggregating ability of meta-analysis allows it to examine 
relationships not investigated in the original primary studies (Arthur et al., 2001), and to test 
hypotheses about sources and magnitudes of heterogeneity and bias (Greenland, 1994).  
Therefore, meta-analysis can be an alternative to a single large, expensive, and logistically 
problematic study (Egger and Smith, 1997); the use of a single study as the basis for risk 
assessments; or the use of purely subjective summary judgments in weight-of-evidence 
determinations.  Meta-analysis can be especially advantageous when research is well-
established and a large number of primary studies are available. 
In a word, meta-analysis, if appropriately conducted, is a tool to quantitatively 
analyze a collection of epidemiological study results, and can be used in risk assessment to 
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 combine results across studies with the goal of estimating measures of association with 
improved precision.  In practice, meta-analysis has been used in the steps of hazard 
identification and dose-response assessment  (Steenland and Savitz, 1997). 
The research goal in this methodology is to use meta-analysis to combine several 
epidemiological datasets to produce an aggregated dose-response function for the 
relationship between bladder cancer risk and arsenic intake from drinking water. 
 
3.1.2. Statistical Theory 
The underlying statistical theory of meta-analysis is “Sample Error Theory”.  The 
sample error stems from the variation of characteristics between samples and the original 
population, given that a sample typically can’t represent the whole population (Arthur et al., 
2001).  There are two major sources of variation to be considered when conducting a meta-
analysis:  (i) within-study variation, resulting from different random sampling errors within 
each study; and (ii) inter-study variation, resulting from the heterogeneity between studies 
(Normand, 1999).  Because of different assumptions about the existence of variations, the 
statistical methods used for meta-analysis then can be broadly classified into two models: (i) 
fixed-effects models, and (ii) random-effects models (Egger et al., 1997). 
 
3.1.2.1. Fixed-effect model 
The fixed-effects model assumes there is only within-study variation in the mean 
outcomes of a study, and inter-study variation can be excluded.  It also assumes that the 
underlying population from which studies are generated is the same and has identical 
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 characteristics and study effect for all studies considered in the meta-analysis (Normand, 
1999).  This is called the homogeneity assumption.      
A fixed-effects model can be expressed as follows (Normand, 1999): 
),(~ 2
.
i
indep
i sNY θ   for i  =1,2,…,k                                                                                 (3.1) 
Where Yi is the summary statistic of each study, which is drawn from the same 
population of study estimates with common mean θ  but independent of each other.  
Therefore, the expected mean of Yi should be equal to the population mean, i.e. E(Yi)=θ .  
And = var(Yi) is the variance of the summary statistic in the ith study, representing how 
well each study sample mean (Y
2
is
i ) estimates θ .   (Figure 3-2) 
 
Figure 3-2. Fixed-effects model. Under the assumptions of the fixed-effects model, the 
expected mean of each study specific statistics, Yi, should be equal to the population 
mean, i.e. E (Yi) =θ . And the difference among these studies only rest on = var(Yi) 
(Normand, 1999). 
2
is
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 3.1.2.2. Random-effects model 
The random-effects model assumes both within-study and between-study variations 
exist.  The population from which studies are generated may have different characteristics 
and study effect.   This assumption leads to wider and more conservative confidence intervals 
than the fixed effects model (Normand, 1999). 
A random-effects model can be expressed as follows (Normand, 1999): 
),(~ 22
. τθ +i
indep
sNYi                                                                                                    (3.2) 
This model can be further deconstructed.  First, the study summary statistic (Yi), 
drawn from a distribution with study-specific mean iθ  and variance , is normally 
distributed, shown as follows: 
2
is
),(~ 2
.
,| 2 ii
indep
Si
sNY
iI
θθ                                                                                                    (3.3) 
Then, each study-specific mean, iθ  is further assumed to be a draw from some 
superpopulation of effects with mean θ  and variance , where 2τ θ  is the average treatment 
effect and  is the inter-study variation, shown as follows: 2τ
),(~ 2
.
,
| 2 τθθ τθ Ni indep                                                                                                     (3.4) 
Therefore, after averaging over the study-specific effects, the distribution of each 
study summary statistic, Yi, is normal distributed with mean θ  and variance , as 
shown before. (Figure 3-3) 
22 τ+is
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Figure 3-3. Random-effect model.  Each effect, iθ , is drawn from a superpopulation 
with mean θ  and variance  (upper plot).  The study-specific summary statistics, Y2τ i, 
are then generated from a distribution with mean determined by iθ  (denoted by ×  in 
the upper plot) and variance  (lower plot) (Normand, 1999). 2is
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 3.1.2.3. Calculating the Summary Estimator 
Meta-analysis uses a weighted average of the results from the individual studies. Any 
method must follow the general equations for a simple, weighted average of results. 
∑∑= iiiw wywy                                                                                                     (3.5) 
Where wi is the weight of each study, yi is the parameter being estimated of each 
study (here, the slope factor), and wy  is the weighted average of the parameter being 
estimated. 
The weight usually is the inverse of the variance of the result for each study.  The 
larger studies have more influence than the smaller ones (Egger et al., 1997; Steenland and 
Savitz, 1997).  The weight used for a fixed-effects model is 2
1
i
i s
w =  and for random effects 
model is 22
1
ii
i s
w τ+= , where  is the within-study variation and  is the inter-study 
variation.  Normand (1999) summarized some estimators for fixed-effects and random-
effects models, listed in Table 3-1 (Normand, 1999). 
2
is
2
iτ
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 Table 3-1. Summary of estimators for fixed-effects and random-effects models.  
 
Table Source: (Normand, 1999) 
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 3.1.2.4. Test of Homogeneity 
The fixed-effects model assumes that all studies are sampled from the same 
population, so the k study-specific summary statistics share a common mean θ .  A statistical 
test for the homogeneity of study means is equivalent to testing (Normand, 1999). 
H0: kθθθθ ==== ...21  against 
H1: At least one iθ  different. 
The chi-square test can be employed as a basic statistical test of the homogeneity 
assumptions (Wang et al., 1999): 
2
1
22 ~)( −−∑= kiiki YYw χχ                                                                                        (3.6) 
Where w (weight) = 1/ , 2is
_
Y = iii wYw ∑∑ / , and n = number of studies. 
If H0 cannot be rejected, we have to accept the null hypotheses; i.e. the k studies share 
a common mean θ  and are homogeneous.  Otherwise, if H0 is rejected, it may be concluded 
that these study means arose from different populations and are not homogeneous.  Under 
this condition, Normand (1999) suggested to “…continue proceeding by either attempting to 
identify covariates that stratify studies into the homogeneous populations or estimating a 
random-effects model” (Normand, 1999).  Another option is to use a random-effect model 
instead of fix-effect model. 
 
3.1.3. Conducting Steps 
The first step in conducting a meta-analysis is formulating the problem to be 
addressed.  This step includes clearly stating the objectives, the hypotheses to be tested, and 
the subgroups of interest.  The study variables (outcome and exposure) and parameters are 
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 also defined in this step.  The potential confounders should also be identified (Egger et al., 
1997). 
The second step is collection and analysis of the data.  It involves a thorough 
literature search to gather all relevant published and unpublished data.  After using the 
proposed methods and criteria for identifying and selecting relevant studies, one will extract 
and analyze information, and finally perform a statistical meta-analysis and calculate the 
overall effect by combining the data.  A heterogeneity test and sensitivity analysis may also 
be conducted if necessary (Egger et al., 1997). 
The final step is reporting the results.  Besides the result of a statistical combination 
of data, the result of the sensitivity analysis is presented.  A good way to present the result is 
by graphical display, together with the confidence intervals of the results (Egger et al., 1997). 
 
3.1.4. Inorganic Arsenic in Drinking Water and Bladder Cancer: A Meta-Analysis for 
Dose-Response Assessment 
 
3.1.4.1. Introduction 
Several epidemiological studies have shown a positive association between arsenic in 
drinking water and bladder cancer, with a dose-response relationship being evident between 
the amount of arsenic intake and the probability of getting cancer, while other studies have 
shown no association.  Meta-analysis was used here to combine the epidemiological datasets 
from different regions, such as Taiwan, US, Bangladesh, India, Chile and Finland, 
accounting as much as possible for the methodological differences in these studies and the 
population differences.  The research product is an aggregated dose-response function for 
risk calculation. 
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 3.1.4.2. Material and Methods 
 
Search methods 
The criteria for inclusion of epidemiological studies in the present meta-analysis are: 
(i) all studies are of a case-control or cohort studies, and  evaluate the relationship between 
arsenic concentration in drinking water and bladder cancer; (ii) studies are of males, females 
or in both genders combined; studies examine incidence or mortality as the study outcome; 
studies provide information required for the statistical analysis; (iii) studies are published in 
English between 1970 and 2005; and (vi) studies are referenced in the U.S. EPA IRIS 
(Integrated Risk Information System), NRC’s (National Research Council) Reports (NRC, 
1999; NRC, 2001) or Medline database.  Besides these searches, the list of references in the 
identified articles was also systematically examined for additional studies. 
The study outcomes varied among studies.  In cohort studies, relative risks were used 
as the study outcome; in case-control studies, odds ratios were the outcomes.  Considering 
that bladder cancer is a rare disease, the odds ratio was assumed approximately the same as 
relative risk, and relative risk was used as the study outcome.  Only one cohort mortality 
study (Lewis et al., 1999) used SMR (standardized mortality rate) as the study outcome.  But 
this study was criticized because “the comparison of the study population to all of Utah is not 
appropriate for estimating excess risks” and “the study is not powerful enough to estimate 
excess risks with enough precision to be useful for arsenic risk analysis” (USEPA, 2001).  
Hence it was excluded in this meta-analysis.   
Seven studies were included in the meta-analysis since they satisfied the criteria 
mentioned above.  They were from different regions, including Taiwan, U.S., Argentina, 
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 Chile and Finland (Bates et al., 1995; Chiou et al., 1995; Kurttio et al., 1999; Chiou et al., 
2001; Moore et al., 2003; Steinmaus et al., 2003; Bates et al., 2004).  Most of the study 
outcomes were adjusted by factors of age, gender and cigarette smoking.  The details of these 
studies are listed in Table 3-2. 
 
Rescaling of Exposure 
As for deciding the exposure midpoint assigned to a subpopulation, if the highest 
category of arsenic exposure was open-ended, its interval was set to equal to the width 
between 0 and the lower bound of the open-ended boundary.  For example, in the study of 
Chiou et al. (2001), the highest category of arsenic exposure was open-ended (>100); this 
open-ended interval was set to equal the width between 0 and 100, and its midpoint was 150.  
If the lowest category was open-ended, the lowest boundary was considered as zero.  The 
upper- and lower-bound values of arsenic concentration in each category were then used to 
calculate the mid-point of exposure for that subpopulation (Norat et al., 2002).  Also, the 
definition of arsenic exposure varied among studies.  In most of the articles, “arsenic 
exposure” means the annual average concentration of arsenic in drinking water (in units of 
µg/L or ppb).  Studies using another exposure index (i.e. lifetime exposure) were rescaled to 
concentration assuming population-average rates of water ingestion. 
 
Dose-response Model 
For each study, using the information on RR (relative risk) and average arsenic 
concentration (X) for each subpopulation, the hazard as a function of exposure can be 
modeled as (Greenland and Longnecker, 1992): 
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 lnRR = b∆X or  lnRR=b(X-X0)                                                                                (3.7) 
where X is the exposure (in µg/L), ∆X is the difference in arsenic concentration 
intake between each category of exposure (X) and the reference category in each study (X0).  
The coefficient b is the fitted slope factor in the linear-logistic regression model.  This linear-
logistic model estimates the logarithm of the observed relative risks (estimated as the odds 
ratio in some studies), and accounts for the correlation between risk estimates for separate 
exposure levels depending on the same reference group. 
After finding the coefficient (bi) of each study, the summary estimate is the pooled 
coefficient (b ).  The individual slopes of each study were combined by weighted average, 
using the inverse of their variances as weights.  The 95% confidence intervals (CI) were 
calculated for the common regression slopes.  The fixed-effect model was first used and the 
homogeneity test was conducted.  The random-effect model was applied when the 
homogeneity test provided evidence of heterogeneity. 
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 Table 3-2. Studies of Bladder Cancer (188)  
Study Study Type Location
Arsenic 
Exposure 
(µg/L) 
Exposure 
Midpoint 
(µg/L) 
Study 
Outcome 
Adjustme
nt 
Chiou et 
al., 1995 Cohort 
SW 
Taiwan 
 
<=50 
50-70 
71+ 
 
25 
60 
100 
Relative Risk 
1.0 
1.8 
3.3 
Age, sex, 
cigarette 
smoking 
Bates et al., 
1995 
Case-
Control Utah, US 
 
<440 
440-<707
707-<987
>=987 
 
220 
600 
850 
1200 
Odds Ratio 
1.0 
0.69 
0.54 
1.0 
Age, sex, 
cigarette 
smoking 
 
Kurttio et 
al., 1999 
Case-
Control Finland 
 
<0.1 
0.1-0.5 
>=0.5 
 
0.05 
0.3 
5 
Odds Ratio 
1.0 
1.53 
2.44 
Age, sex, 
cigarette 
smoking 
 
 
Chiou et 
al., 2001 
 
Cohort NE Taiwan 
 
<=10 
10.1-50 
50.1-100
>100 
 
5 
30 
75 
150 
Relative Risk 
1.0 
1.5 
2.2 
4.8 
Age, sex, 
cigarette 
smoking, 
and 
duration 
of well 
water 
drinking  
Steinmaus 
et al., 2003 
Case-
Control 
Westen 
US 
Californi
a & 
Nevada) 
 
<10 
10-80 
>80 
 
5 
45 
120 
Odds Ratio 
1.0 
1.04 
0.94 
Age, 
gender, 
occupatio
n, 
smoking 
history 
Moore et 
al., 2003 
Case-
Control 
Argentina 
& Chile 
 
<10 
10-99 
100-299 
>300 
 
5 
55 
200 
400 
Odds Ratio 
1.0 
1.46 
2.26 
1.36 
Tumor 
stage and 
grade 
Bates et al., 
2004 
Case-
Control Argentina
 
0-50 
51-100 
101-200 
>200 
 
25 
75 
150 
300 
Odds Ratio 
1.0 
0.88 
1.02 
0.6 
Multivari
ate-
adjusted 
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 3.1.4.3. Results 
 
Dose-Response Slope of Each Study 
From Figure 3-4, we can see that the results of observational studies of arsenic in 
drinking waster are quite dispersed.  In three studies (Bates et al. 1995, Steinmaus et al. 2003, 
and Bates et al. 2004), a dose-response relationship is not evident between the exposure to 
arsenic and the relative risk of bladder cancer, or is negative.  In the study of Kurttio et al. 
1999, a much stronger relationship is noted from the limited and lower range of arsenic 
exposure.  Although two studies done by Chioe et al. (1995 and 2001) are different study 
designs from two different regions in Taiwan, their dose-response relationships are quite 
similar. 
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Bates et al.
(2004)
Steinmaus et
al. (2003)
 
Figure 3-4. Dose-response analysis of relative risk of bladder cancer for arsenic intake 
from Drinking water. 
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 Calculating the Summary Estimator and Test of Homogeneity 
The fixed-effect model was first used, with the weight calculated by the inverse of 
variance of each study, i.e. 2
1
i
i s
w = .  By using the statistical software of Stata, the pooled 
estimate of slopes from seven studies was 0.00615 (95% CI: 0.00588, 0.00642), with the unit 
of lnRR per unit increase of exposure (i.e. per µg/L).  But the chi-square statistic was quite 
large (i.e. Q= 3197.110 on 6 degrees of freedom, p= 0.00), which rejects the null hypothesis 
of homogeneity and means there was evidence of heterogeneity. 
The fitted slope (with the unit of lnRR per unit increase of exposure) of each study 
and the combined estimate of slope by using fixed-effect model are presented as box plots in 
Figure 3-5.  The horizontal line of each study corresponds to its 95% confidence interval, and 
the size of the square reflects the weight of each study.  From Figure 3-5, it is clear that the 
Finland study done by Kurttio et al. (1999) has a much wider horizontal line and no box, 
showing that its 95% confidence interval is much wider than other studies but with very little 
weight.  We then concluded that this study might be an outlier for its far lower arsenic 
exposure.  This study was then excluded to solve the problem of heterogeneity.  A sensitivity 
analysis was conducted to make sure the exclusion of the Finland study done by Kurttio et al. 
(1999) doesn’t cause significant effect on the result, which will be discussed later.  But this 
didn’t lower the value of the chi-square statistic sufficiently, showing that heterogeneity still 
exists even in the remaining subset of six studies.  Therefore, a random-effect model was 
used next. 
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Figure 3-5. Slope (with the unit of lnRR per unit increase of exposure) of each study 
and the combined estimate of slope by using fix-effect model.  The horizontal line of 
each study corresponds to its 95% confidence interval, and the size of the square 
reflects the weight of each study. 
 
 
By using the random-effect model, the pooled estimate of the slopes from six studies 
was found to be 0.004 (lifetime excess probability of bladder cancer per µg/L) (95% CI: -
0.003, 0.012).  The results are shown in Figure 3-6. 
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Figure 3-6. Slope (with the unit of lnRR per unit increase of exposure) of each study 
and the combined estimate of slope by using random-effect model. 
 
 
Sensitivity Analysis 
To make sure the exclusion of the Finland study done by Kurttio et al. (1999) doesn’t 
cause significant effect on the result, another meta-analysis of using random-effect model 
and including all seven studies was also conducted.  The average of the slopes is 0.005 (95% 
C.I.: -0.002, 0.012).  Comparing this result with the previous one using the random-effect 
model but excluding the Finland study, their best-estimates are only slightly different (0.004 
vs. 0.005), and the difference between them will be even slighter when exponential functions 
are applied to these two values.  Also, their upper-bound estimates are the same (i.e. 0.012).  
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 Therefore, it is appropriate to exclude the Finland study.  The comparison of these results is 
shown in Table 3-3.  Figure 3-7 shows both the summary estimators from the fixed-effect 
model (including all seven studies) and random-effect model (including six studies). 
 
Table 3-3. Comparison of the Results by using Different Models and including Different 
Studies. 
STUDIES INCLUDED MODEL BEST-ESTIMATE LOWER UPPER 
Fixed-effect 0.006 0.006 0.006  
7 Random-effect 0.005 -0.002 0.012 
Fixed 0.006 0.006 0.006  
6 Random 0.004 -0.003 0.012 
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Figure 3-7. Dose-response relationship of relative risk of bladder cancer for arsenic 
intake from Drinking water by using fixed-effect and random-effect model. 
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 Risk Calculation 
The result of meta-analysis supports the claim that there is a positive dose-response 
relationship between exposure to arsenic in drinking water and bladder cancer.  Using the 
results presented above, the best estimate of the relative risk associated with an increase of 
arsenic exposure can be estimated as lnRR = 0.004X, or RR= EXP (0.004X), were X is the 
waterborne arsenic concentration in units of µg/L.  Using the upper 95% confidence limit, 
the plausible upper limit of the relative risk associated with an increase of arsenic exposure 
can be estimated as lnRR = 0.012X, or RR= EXP (0.012X).  
The absolute risk (AR) of bladder cancer is calculated by multiplying the excessive 
relative risk (ERR) by the natural rate (NR) of bladder cancer.  Excess relative risk equals to 
the relative risk minus one (i.e. ERR=RR-1).  Therefore, AR can be calculated as: 
AR= NR×ERR = NR (RR-1)= NR× ×{EXP (0.012X)-1}                                        (3.8) 
Table 3-4 and Figure 3-8 show the results of the AR calculation for bladder cancer 
associated with a variety of proposed MCLs (maximum contaminant levels) by using the 
different estimates from the meta-analysis: the best estimate, the upper and lower bound 
estimates of the slope factors.  At the most recent arsenic MCL (i.e. 10µg/L), the associated 
bladder cancer risk (lifetime excess probability) is 2.29× 10-5 by using the upper bound 
estimation of slope factor. 
From the upper bound result of the meta-analysis, the arsenic concentration 
corresponding to a lifetime excess probability of 10-3 is approximately 160 µg/L; the 
concentration corresponding to 10-4 is approximately 40 µg/L; and the concentration 
corresponding to 10-5 is 4.5 µg/L. 
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 Table 3-4. Risk of Bladder Cancer at different MCLs 
MCL (ppb) AR (U_95) AR (Mean) AR (L_95) 
0 0 0 0 
1 2.17E-06 7.21E-07 -5.47E-06 
3 6.60E-06 2.17E-06 -1.59E-05 
5 1.11E-05 3.64E-06 -2.57E-05 
10 2.29E-05 7.35E-06 -4.78E-05 
20 4.88E-05 1.50E-05 -8.29E-05 
50 1.48E-04 3.98E-05 -1.41E-04 
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Figure 3-8. Absolute Risk of Bladder Cancer at different proposed MCLs (Maximum 
Contaminant Levels) from meta-analysis. (Mean: the best estimation of slope factor, 
U_95: the upper bound estimation of slope factor) 
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 Aggregated slope factors for dose-response relationship.   
The slope factor was fitted using the equation of Pc = SF×ADRI, where Pc is the mean 
probability of cancer, SF is the slope factor, and ADRI is average daily rate of intake of 
arsenic (µg/kg/day).  ADRI (µg/kg/day) was transformed from arsenic MCL (µg/L or ppb) 
by assuming a tap water ingestion rate of 0.023 L/kg-day.  A linear function (characterized 
by a slope factor) was then fitted as an approximation to the dose-response curve for the 
meta-analysis results.  Figure 3-9 shows the regression results of slope factors.  The best 
estimate of the slope factor from the meta-analysis is 3.0×10-5 (with unit of probability per 
µg//kg/day), with the upper bound of 1.27×10-4.  These slope factors from the meta-analysis 
are lower than the ones from the EPA (1.15×10-3) and NRC (8.85×10-4). 
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Figure 3-9. Slope Factors of Bladder Cancer generated from Meta-analysis Results. 
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 3.1.5. Conclusion and Discussions 
In this study, a meta-analysis of arsenic studies was conducted by combining several 
epidemiological studies from different regions (such as Taiwan, US, Argentina, Chile and 
Finland) to produce a composite dose-response relationship between the amount of arsenic 
exposure and the excess probability of cancer.  Both the fixed-effect and random-effect 
models were used to calculate the averaged coefficient of the linear-logistic regression model.  
A homogeneity test was conducted first to check the heterogeneity among these studies.  
Because the heterogeneity was found to be high, a random-effect model had to be used.  This 
results in a wider confidence interval of slopes and a more conservative upper bound 
quantitative summary of risk.  The high heterogeneity shows that there are large differences 
between studies, which suggests it may not be appropriate to simply extrapolate from 
Taiwanese studies to the U.S. 
The final product is an aggregated dose-response model in the range of empirical 
observation of arsenic.  The best estimate of the slope factor from the meta-analysis is 
3.0×10-5 (with unit of probability per microgram/kg/day), with the upper bound of 1.27×10-4.  
These slope factors from the meta-analysis are lower than the ones from the EPA (1.15×10-3) 
and NRC (8.85×10-4).  There clearly are large differences between the current study and the 
EPA/NRC results.  The possible reason for the difference is because EPA/NRC conducted 
their study mainly based on data from Taiwan, while we used meta-analysis to combine data 
from several different regions. 
Considering the most recent arsenic MCL (i.e. 10 µg/L), the associated bladder cancer 
risk (lifetime excess probability) conducted using the upper bound result of the meta-analysis 
is 2.29 10× -5 (7.35 10× -6 if the best estimate is used), which is much lower than NRC’s 
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 theoretical lifetime excess risk of bladder cancer for U.S. Populations (1.2×10-3 for female 
and 2.3×10-3 for male).  These results show that the existing estimates of risk of bladder 
cancer provided by the EPA and NRC may be overestimates. 
One shortcoming of this study is that there are only seven observational studies 
available for meta-analysis.  The available data make it difficult to do further investigation, 
such as meta-regression to check whether an overall study result varies among subgroups (e.g. 
study type or location), or a sensitivity analysis to detect the robustness of the findings to 
different assumptions.  New observational studies of arsenic, especially ones involving a 
case-control or cohort design, need the investment of large amounts of money and time.  
Even given that requirement, meta-analysis can be an appropriate tool to resolve the 
discrepancies among existing epidemiological data, and to produce a reasonable generalized 
dose-response model and its distribution of parameter values. 
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 3.2. The Quantification of Margin of Safety 
 
3.2.1. Margin of Safety and Regulatory Rationality 
Maximum Contaminant Levels (MCLs) are selected to provide a margin of safety for 
the protection of public health in the face of inter-subject variability and uncertainty.  The 
margin of safety is not quantitatively defined yet, but is known to be related to variability and 
uncertainty.  The margin of safety generally increases as the fraction of a population 
predicted to be below a target risk is increased and as the confidence in this claim increases.  
Therefore, the goal of this research is to better quantify the margin of safety by probabilistic 
risk assessment, dealing with variability and uncertainty issues, and to relate this margin of 
safety to compliance costs.  This will help to develop regulatory limits on a contaminant 
concentration that adequately protects human health with an ample margin of safety at a 
more reasonable cost than currently is the case. 
In this study, a key assumption is that lower MCLs associated with increasing 
margins of safety come at increased cost of compliance, and that decision-makers must 
understand the price of any such increased margin of safety.  A central idea here is that the 
increased cost of a lower MCL must be viewed in part as purchasing a larger margin of 
safety, rather than purchasing some established reduction in health effects (the magnitude of 
which remains uncertain). 
The rationality of this research can also be understood through the following figures.  
Figure 3-10 shows one example of the traditional approach in risk-based decision making.  In 
that figure, the best estimate of the risk (i.e. probability of getting cancer, Pc) is obtained for 
a representative individual in the exposed population. As the MCL is lowered, this reduces 
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 the risk to this representative individual, and so the increased cost associated with a lower 
MCL may be viewed as producing a reduction in the risk.  Since the individual risk is 
reduced, so is the total burden of effects in the exposed population.  As a result, the increased 
cost associated with a lower MCL may be viewed as “purchasing” a reduction in health 
effects in the affected population. 
 
0
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0 10 20 30 40 50 6
Arsenic MCL (ppb)
M
ea
n 
va
lu
e 
of
 P
0
 
Figure 3-10. A hypothetical relationship between MCL and the “best estimate” of risk 
(P) to a representative individual in the exposed population (using a linear dose-
response model). 
 
Consider, however, the variability of risk across the population.  This is shown in 
Figure 3-11.  Note that lowering the MCL increases the fraction of the population whose risk 
is below a certain target risk, such as a value of Pc equal to 10-4.  The increased cost 
associated with a lower MCL may be viewed as “purchasing” an addition in the fraction of 
individuals whose risk is below the target level of risk we have established. 
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Figure 3-11. A hypothetical relationship between arsenic MCL and the fraction of 
a population whose risk below 10-4 (using a linear dose-response model). 
 
 
Then the issue of uncertainty is considered by asking: “With what confidence can we 
state that at least some target fraction of the population (e.g. 90%) is below the target risk 
(e.g.10-4)?  This is shown in Figure 3-12 as an example.  Note that lowering the MCL raises 
the confidence that at least 90% of the population is below the target risk of 10-4.  The 
increased cost associated with a lower MCL may be viewed as “purchasing” increased 
confidence that the fraction of individuals whose risk is below the target risk is acceptable. 
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 At Least 90% Population being Protected
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Figure 3-12. A hypothetical relationship between MCL and the confidence that at least 
90% of the population whose risk is below 10-4 or 10-5 (in other words, no more than 
10% of the population whose risk is above 10-4 or 10-5). 
 
The above discussion suggests that each potential MCL can be described by a three 
dimensional volume containing points described by a triplet of values: (Pc, F, C), where Pc is 
the probability of getting cancer, F is the fraction of the population whose risk is below this 
value of Pc, and C is the confidence with which the assessor can state that at least this 
fraction of the population is protected from a risk with the value of Pc.  For example, suppose 
the MCL is fixed (e.g. 5 ppb).  Figure 3-13 shows the surface of confidence (C) associated 
with this MCL, where the X and Y axes are F (fraction of the population with a risk below a 
given value of Pc) and Pc, respectively.  Note that as the value of Pc is reduced at a given 
value of F, the surface height decreases, since the confidence that AT LEAST this fraction of 
the population experiences a risk below Pc decreases.  Similarly, as the target fraction 
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 increases at a given value of Pc, the confidence that this target fraction is not exceeded 
(protected) decreases also. 
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Figure 3-13. A hypothetical surface showing the confidence (C) with which it can 
be stated that at least certain fraction (F) of the population experience a risk below 
a target risk (Pc). 
 
From a policy perspective, the existence of this surface suggests that the desirability 
of an MCL will depend on where Pc, F and C are set as targets.  Clearly, this desirability 
increases as the target values of Pc are decreased and F are increased, but this is offset by 
decreased confidence that at least these values are achieved.  If one imagines a series of these 
surfaces, one for each potential MCL, one can imagine that reducing the MCL (with its 
associated increase in cost) may be viewed in three ways: (i) it reduces the mean, or 
expectation, value of Pc in the population, and hence the expectation value of the total 
burden of effects; (ii) it increases the fraction F, conditional on target values of Pc and C; or 
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 (iii) it increases the confidence, C, in protection conditional on target values of Pc and F.  As 
a result, the goal of this research is three-fold:  
• to develop the methodologies needed to generate these surfaces, 
• to develop a decision methodology for choosing an appropriate MCL given multiple 
surfaces at potential MCLs, and 
• to test the methodologies in the case of arsenic in drinking water using the results of the 
meta-analysis performed in last section. 
 
3.2.2. Reasoning for the Arsenic Case 
Applying the previous regulatory reasoning to the arsenic case, a regulator should be 
able to identify an MCL that provides some pre-specified level of confidence that at least a 
prescribed or target fraction of the population will be protected against a risk that exceeds Pc 
after the regulatory limit is in place.  Lowering or tightening the allowed concentration limit 
(i.e. MCL) then increases the confidence that this action has purchased protection of some 
specified fraction of the population against some specific risk.  In a very real sense, the cost 
of the regulatory action may be justified by the increased confidence that a desired state of 
health has been reached.  Therefore, the central question facing a decision-maker can be 
stated as: “What is the MCL for which it can be said with at least C (%) confidence that no 
more than F (%) of the population will be exposed to target risks of Pc or greater?” And the 
auxiliary research question is: “What is the incremental cost associated with an incremental 
increase in the margin of safety, characterized by an increase in C (confidence) and decrease 
in F (fraction of population above a risk of Pc)?” 
More specifically, my step-by-step reasoning is listed in Table 3-5. 
 
75  
 Table 3-5. Steps of Reasoning 
STEP REASONING 
1 EPA’s old limit was 50 µg/L. 
2 New information in the 1990’s suggested 50 µg/L was not protecting health (Pc was 
above 10-4). 
3 EPA proposed 10 µg/L based on these data.  This level was determined to be 
feasible technologically and economically. 
4 The new NAS analysis of epidemiological data shows significant risk at 10 µg/L (Pc 
> 10-4) if linear model is used. (Linear model might not be the best model to estimate 
dose-response relationship.) 
5 This suggests that the MCL should be below 10 µg/L to prevent the lifetime risk of 
getting cancer above from exceeding 10-4. 
6 The cost of lowering the MCL to below 10 µg/L is high. (Gurian and Small, 2001) 
7 However, the risk estimate contains a margin of safety (e.g. linear model). 
8 A “reasonable” margin of safety might still be associated with an MCL of 10 µg/L 
or above. 
9 Therefore, the MCL might be chosen by establishing a target level of health risk and 
an appropriate margin of safety, and then locating a concentration that meets these 
goals. 
10 Performing the analysis in step 9 requires answering several questions:  
(1) What are the uncertainty and variability probability density functions (PDFs) or 
cumulative density functions (CDFs) of cancer risk for different MCLs? 
(2) How much confidence can we have that an MCL of 1, 3, 5, 10 etc. will still 
produce acceptable risk, which is defined as some combination of target risk and 
fraction of population protected? 
(3) What is meant by a “reasonable margin of safety” for SDWA decisions taking 
into account variability and uncertainty? 
11 For each MCL, one can then calculate the margin of safety and the cost, producing a 
curve relating these two quantities, which in turn can be used to select an MCL that 
produces a “reasonable margin of safety” at acceptable cost. 
 
3.2.3. Nested Variability/Uncertainty Analysis by Monte Carlo Simulation  
Monte Carlo simulation is popularly used to address variability and/or uncertainty in 
probabilistic risk assessment.  In the nested Monte Carlo methodology, the variability of each 
parameter is specified as a probability distribution.  Then, a set of parameter values needed 
 
76  
 for modeling is drawn from these distributions and the risk is calculated.  This process is 
repeated numerous times over multiple draws from the distributions, accounting for 
correlations (Greenland, 2001).  The result is a realization of the variability distribution. 
Using uncertainty distribution, the above process is repeated to generate a new realization of 
the variability distribution.  The procedure of applying Monte Carlo analysis in exposure 
assessment is shown in Figure 3-14.  Some computer software, such as Crystal Ball, can 
easily do the Monte Carlo simulation, assuming the underlying model is sufficiently simple 
so it can be executed in Excel. 
 
Figure 3-14. Schematic and flowchart illustrating the application of Monte Carlo 
analysis to a model (Cullen and Frey, 1999). 
 
The influence diagram in Figure 3-15 illustrates the steps of risk calculation taken in 
the present study on arsenic.  Crystal Ball software was used to do the simulation.  The result 
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 of the simulation is a quantitative assessment of the uncertainty in estimates of the percentile 
of the inter-subject variability distribution associated with a given level of risk.  Using nested 
variability /uncertainty methods, the simulation can be used to place an uncertainty 
distribution (PDF or CDF) on the estimate of the fraction of exposed individuals with a 
probability of cancer below 10-4 (or any other target value of Pc).  By generating such 
distributions, one can produce a 3-D surface with one axis being probability of cancer (Pc), 
another being fraction of people below that probability of cancer, and a third being 
confidence that this fraction is not exceeded at the MCL considered. 
 
Figure 3-15.  Influence Diagram for Steps of Risk Calculation employed in the study. 
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 3.2.4. Methods 
The margin of safety is related to inter-subject variability of risk and to uncertainty.  
Several model inputs were considered for contributing inter-subjective variability (in 
parameter values, activity patterns, etc) or uncertainty (in modeling, parameter values and 
low-dose extrapolation, etc).  They are listed as follows.  How to incorporate them into risk 
characterization will be discussed in the following sections. 
(1) Variability between individuals (Inter-subject variability) 
• Intake rate per unit body weight (IR/BW). 
• Variability of secondary pathway parameters. 
• Susceptibility (e.g. retention times; bioactivation fractions). 
• No variability in water concentration was assumed since exposure at the MCL is 
examined. 
• No variability in exposure duration was assumed (a lifetime exposure of 75 years is 
assumed). 
(2) Uncertainty (in modeling, parameter values and extrapolations between species and/or 
subpopulations) 
• Median values of variability Probability Density Functions (PDFs). 
• Dose-response relationships. 
 
3.2.4.1. Variability Analysis 
The model inputs needed to establish the magnitude of exposure for an individual 
include Cw, IR/BW, ED and AT.  Cw is the arsenic concentration to which a person is 
exposed; here this is the regulatory levels we are interested in assessing: 1, 3, 5, 10 and 20 
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 µg/L.  IR/BW is total tap water intake per unit body weight (L/kg-day) for an individual in a 
given age group.  Information on IR/BW was obtained from Table 3-7 of the EPA’s 1997 
Exposure Factors Handbook (USEPA, 1997). ED (duration of exposure) is assumed equal to 
the length of time represented by an age category, and AT (averaging time) is assumed to be 
the average years of life (75 years).  The Average Daily Rate of Intake (ADRI, the unit of 
exposure used in this study) was calculated by the following formula: 
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The age-weighted ADRI was calculated considering the changes in the above 
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In using an age-weighted value for ADRI, it is implicit that the health effects are 
independent of the time-history of exposure; data and models needed to correct for this 
assumption are not available at present (Cullen and Frey, 1999).  The age-weighted ADRI 
was assumed to have a lognormal distribution in the population when everyone is exposed at 
the same concentration (at the proposed MCL).  Inter-subject variability in ADRI is 
dominated by inter-subject variability in IR/BW for each age category, which in turn was 
determined from the cumulative distribution function percentiles represented by the data in 
Table 3-7 of the 1997 Exposure Factors Handbook cited previously.  A lognormal 
 
80  
 distribution was fit to these data in each age category, with best fits resulting from a GSD of 
approximately 1.75 in each category (it varied between 1.6 and 1.9 across the age categories, 
with a mean of 1.75).  It then was assumed that an individual’s z-statistic for a given 
parameter is invariant with age.  With this assumption, the age-weighted value of ADRI 
(Equation 3.10) will also be distributed lognormally with a GSD of 1.75.  The median value 
of the age-weighted ADRI was calculated as the product of the mean age-weighted ADRI 
(from Equation 3.10) and EXP{-[LN2(GSD)]/2} (the ratio of median over mean for 
lognormal distributions).  Uncertainty is negligible compared to that introduced by dose-
response models (described below), and so is not considered further here.  Appendix A 
shows the details of calculation steps. 
 
3.2.4.2. Uncertainty analysis 
Five dose-response models, shown in Table 3-6, were considered to reflect 
uncertainty in the dose-response equation. These models are Mitosis (Crawford-Brown, 
2001), Repair (Crawford-Brown, 2001), NAS (NRC, 1999), Linear New (Morales et al., 
2000) and Upper Morales (Morales et al., 2000).  They were fit to the data on bladder and 
lung cancer of Morales et al .(Morales et al., 2000), ignoring liver cancer since, as detailed in 
the NAS reports, the particular forms of liver cancer noted in the Taiwanese population do 
not correspond to those expected within the U.S. population (NRC, 1999; NRC, 2001).  The 
Agency report also indicates that non-cancer effects are likely to be significant only at 
concentrations well above those considered here, so cancer risk is likely to be the driving 
effect in regulatory decisions (USEPA, 2001). Total fatal and non-fatal cancers are combined 
here. 
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 Morales and her colleagues (Morales et al., 2000) utilized 10 separate models in 
interpreting the dose-response data, including variations of the generalized linear and 
multistage-Weibull models. Their results indicated little ability to distinguish between the 
model fits, although the generalized linear models provided marginally more robust and 
stable results. Available scientific evidence suggests that arsenic does not act as a direct 
carcinogen through interaction with DNA (USEPA, 2001).  The limited evidence available 
points towards a mode of action in which arsenic either is toxic, inducing some form of 
proliferative response, or interfering with repair of DNA damage. In light of this evidence, 
the data of Morales et al. were fit in the current study with an alternative set of models based 
on multistage theories of carcinogenesis. In particular, the Moolgavkar model (Moolgavkar 
et al., 1990), involving transitions between normal cells, initiated cells and a full tumor, was 
employed after modification for repair following the state-vector models of Crawford-Brown 
and Hofmann (Crawford-Brown and Hofmann, 1993; Crawford-Brown and Hofmann, 1996). 
In these models, background transitions occur between normal, initiated and tumor states, 
with proliferation in the initiated state and repair from initiated back to normal calls. The 
mitosis model presupposes that arsenic primarily increases the mitotic rate in the initiated 
pool of cells, while the repair model presupposes that arsenic primarily reduces the repair 
rate constant. The differential equations for the mitosis and repair models are as follows: 
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 where kni is the transition rate constant from normal to initiated cells (probability per 
unit time); kit is the transition rate constant from initiated to tumor cells (probability per unit 
time); kr is the repair rate constant from initiated to normal cells cells (probability per unit 
time); M is the net growth rate constant for the pool of initiated cells (probability per unit 
time); Nn(t) is the number of normal cells; Ni(t) is the number of initiated cells; Nt(t) is the 
number of tumor cells. It is assumed that the probability of cancer is proportional to the 
number of tumor cells generated over a lifetime of 73 years.  For arsenic exposure, either the 
repair rate constant (for the repair model) or the net mitotic rate (for the mitosis model) was 
assumed a function of arsenic concentration in water. For the repair model, this function was 
linear in concentration (i.e. the repair rate constant declined linearly with concentration). For 
the mitotic model, this function was quadratic in concentration (Crawford-Brown et al., 
2002). 
The biologically-based models were solved through numerical integration of the 
underlying differential equations, with the initial values in the normal, initiated and tumor 
states being 1, 0 and 0, respectively. The best-fitting value of kit was 6×10-7 per day. The 
best fitting ratio of values of kni/kr at background was 0.075.  The value of M was 0.002 per 
day at background. For the repair model, the best-fitting equation for the relationship 
between kr and arsenic concentration was: 
kr  =  0.01 - (1.3×10-6 ×C)                                      (3.14) 
where C is the concentration of arsenic in units of µg/L and kr is in units of 
probability of repair per day. For the mitotic model, the best-fitting equation for the 
relationship between M and arsenic concentration was: 
M  =  0.002 + (1.8×10-10×C2)                                     (3.15) 
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 where C is the concentration of arsenic in units of µg/L and M is in units of net 
probability of mitosis per initiated cell per day (i.e. the difference between the mitotic and 
apoptotic/cell death rates).  
Results of the model fits are shown in Table 3-6.  Pc in the table is the mean 
probability of cancer at a benchmark concentration of 10 µg/L of arsenic, assuming a tap 
water ingestion rate of 0.0226 L/kg-day.  A benchmark dose approach was adopted in which 
(i) a best fit of each separate model to the data was obtained; (ii) the model was used to 
estimate the value of Pc at 10 µg/L; and (iii) a linear function (characterized by a slope factor) 
was fitted between the origin and this benchmark as an approximation to the dose-response 
curve for that model. The sum of confidence over all models was set equal to unity, and it 
was assumed that all five models are equally likely, giving each one the same confidence (p 
= 0.2).  This latter assumption was made because the mode of action of arsenic has not been 
well established. 
 
Table 3-6. Results of Different Dose-response Models for Arsenic Used in the Current 
Study (Showing the Difference in Predicted Values of Pc at 10 µg/L) 
MODELS Pc ([As]= 10 µg/L) EQUIVALENT SLOPE FACTORS 
SUBJECTIVE 
CONFIDENCE 
Mitosis 1.00E-06 4.42E-06 0.2 
Repair 9.60E-05 4.25E-04 0.2 
NAS 2.00E-04 8.85E-04 0.2 
Linear New 3.50E-04 1.55E-03 0.2 
Upper Morales 6.00E-04 2.65E-03 0.2 
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 3.2.5. Results 
 
3.2.5.1. Cumulative Distribution Functions (CDFs) of Pc 
By running the Monte Carlo simulation using the PDF for ADRI, the variability of 
risk (probability of cancer, Pc) at each MCL under each different model was estimated. The 
resulting variability cumulative distribution functions (CDFs) for each examined MCL and 
model are shown in Figures 3-16 (A through E).  The y-axis, CDF(Pc), represents the 
fraction of population with risk at or below the value of Pc on the x-axis.  As expected, the 
figures demonstrate that more stringent MCLs yield a larger proportion of population 
protected at each target value of Pc for each model. 
 
3.2.5.2. Fraction of Population below a Target Risk Level 
The fractions of population at or below a given risk level were extracted from the five 
CDFs of Pc (Figure 3-16).  The extracted results for each model are provided in Table 3-7 
and shown in Figure 3-17, which shows that this fraction increases as the MCL is reduced, 
conditional on each of several target values of Pc (10-4 and 10-5). 
Using MCL=1 µg/L as an example, we can say that by using the Upper Morales 
model, there will be at least 84% of the population protected from a cancer risk of 10-4 at this 
MCL, but only 2% of the population is protected from a cancer risk of 10-5 at the same MCL. 
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Figure 3-16. Relationship between probability of cancer (x-axis) and fraction of population below this value of Pc (F, or CDF(Pc)) 
under different models and MCLs. 
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Table 3-7. Fraction of Population whose Value of Pc Exceeds the Target Value of Pc (10-4 or 10-5). 
Figure 3-17. Relationships between Arsenic MCLs and the fraction of population protected from the tar get risk. 
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 3.2.5.3. Confidence Analysis 
As described in the previous sections, there are several alternative models for 
calculating the probability of cancer from arsenic in drinking water.  The differences among 
the predictions of these models cause uncertainty in determining the true risk to the 
population.  In order to account for this uncertainty, 5 dose-response models listed in Table 
3-6 were considered and a confidence analysis to address the uncertainty was conducted. 
The sum of confidences (over all models) is bounded by unity, and it was assumed 
that each model is equally likely in terms of prediction power, i.e. each model was assigned a 
confidence of 0.2.  Extracted from the results of the Monte Carlo simulation in the previous 
section (the variability distributions for the five alternative dose-response models, shown in 
Figure 3-16 previously), new information can be obtained on the confidence that a given 
fraction of population (F) is protected at each value of Pc at each MCL.  Table 3-8 and 
Figure 3-18 are examples, assuming the target value of F is 90%.   
 
Table 3-8. The Calculated Pc from Monte Carlo Simulation at different MCLs by using 
different models and their confidence, assuming the target value of F is 90%. 
Models Mitosis Repair NAS Linear New Upper Morales
MCL (ppb) Pc Pc Pc Pc Pc 
1 2.08E-07 2.00E-05 4.16E-05 7.28E-05 1.25E-04 
3 5.92E-07 5.69E-05 1.18E-04 2.07E-04 3.55E-04 
5 1.05E-06 1.01E-04 2.11E-04 3.68E-04 6.32E-04 
10 1.90E-06 1.82E-04 3.80E-04 6.65E-04 1.14E-03 
20 3.77E-06 3.62E-04 7.55E-04 1.32E-03 2.26E-03 
50 9.10E-06 8.74E-04 1.82E-03 3.19E-03 5.46E-03 
Confidence 0.2 0.2 0.2 0.2 0.2 
CDF(Confidence) 0.2 0.4 0.6 0.8 1 
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Figure 3-18. CDF (Confidence) of protecting 90% of population at risk less than given 
 
Table 3-9 summarizes the results for a variety of MCLs an
Pc and at different MCLs. 
d values of F, and for two 
alues of Pc (10-4 and 10-5).  Bear in mind that these results used the five dose-response 
re equally 
weighted with respect nce
v
models described previously, all were fitted to the data of Morales et al., and all we
to confide . 
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 Table 3-9. Confidence in the Claim that At Least a Fraction of the population (F) will 
have Risk below the Target Value of Pc (10-4 or 10-5). 
 
 
 
3.2.6. Conclusions 
Using the framework above, several distinct questions can be answered.  The primary 
question in this research is about the MCL of arsenic that may be allowed by the U.S. EPA if 
the Agency wishes to claim that a reasonable fraction of the population (F%) is protected 
below any given value of lifetime cancer risk (Pc) at any selected level of confidence (C).  
Obtaining a graphical representation of the relationship between Pc, F, C and MCL to answer 
this question was the focus of this section; since there are multiple variables (MCL, F%, Pc 
and C), it is not possible to display them at once in a single graph. 
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 This issue can be considered from different perspectives by slicing through these four 
imensional volumes.  First, we can fix the factor of the protected population (F) by asking 
the question: “With what confidence can we state that at least some target fraction of the 
population (e.g. 90%) is below the target risk (e.g.10-4 or 10-5)?  This is shown in Figure 3-19 
as an example.  It is easy to compare the confidence at different MCLs and risk targets under 
a fixed protected fraction of the population.  For example, at an MCL of 5µg/L, the 
confidence that at least 90% of the population is being protected from a risk of 10-4 is 0.4, 
while the confidence for a risk target of 10-5 is only around 0.2.  Also, note that for both of 
the risk targets, lowering the MCL raises the confidence that at least 90% of the population is 
below the target risk of either 10-4 or 10-5. 
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Figure 3-19. The Confidence that at least 90% of the population whose risk is below to 
the risk level (10-4 or 10-5) at different MCLs. 
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 Figure 3-20 is another way of considering the same issue, but the fixed factor is 
changed to target risk (or Pc).  The figure illustrates the confidence associated with the 
fraction of the population below a constraining target risk level (10-4) at different MCLs.  
From this graph, it is easy to check how much confidence one can have if the goal is to 
protect a given fraction of the population from a target risk of 10-4 at each MCL.  For 
example, if the regulatory target is that at least 90% of the population witch have a risk lower 
than 10-4, from Figure 3-20, it can be seen that at an MCL equal to 50 µg/L, there is only a 
confidence of 0.2 that this goal will be met.  The confidence increases to 0.55 when the MCL 
is set to 3 µg/L, and increases to 0.9 when the MCL is set more stringently to 1 µg/L.  Also, 
note that increasing the fraction of the population being protected decreases the confidence at 
all MCLs. 
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Figure 3-20. The relationship between Confide
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whose risk below to the target risk level (10 ) at different MCLs. 
 
92  
  
3.2.6.1. Risk Surfaces 
Figure 3-21 is the other way to graphically present the relationships between Pc, F, C 
and MCL.  They are a series of “risk surface”, one for each potential MCL.  Note that 
reducing the MCL can be viewed in three ways from these surfaces: (i) it reduces the mean, 
or expectation, value of Pc in the population, and hence the expectation value of the total 
burden of effects; (ii) it increases the fraction F, conditional on target values of Pc and C; or 
(iii) it increases the confidence, C, in protection conditional on target values of Pc and F. 
 
3.2.6.2. MCL Tables 
The relationships among Pc, F, C and MCL can also be presented in a series of table 
(Tables 3-10 and 3-11) to clearly show what the decision (i.e. MCL) would be at given target 
risk and policy goal (i.e. a given confidence that a certain fraction of the population is being 
protected from this target risk).  For example, when the target risk is set to be 10-5 (Table 3-
10), and the values of F and C are set to 90% and 0.8 respectively, the MCL should be set 1 
µg/L to meet this policy goal; when the target risk is set to be 10-4 (Table 3-11), and F and C 
are retained at 90% and 0.8, the MCL should be set 3 µg/L to meet this policy goal.  By using 
these tables, policy makers can choose a desirable MCL based on different policy goals. 
From these MCL tables, it is evident that the current arsenic MCL of 10 µg/L may 
still be too high at a target risk of 10-5 (Table 3-10).  At a target risk of 10-4 (Table 3-11), an 
arsenic MCL of 10 µg/L becomes more reasonable if the policy maker is willing accept 
values of F and C that are in the neighborhood of 60% and 0.6 (or 70% and 0.5).  Otherwise, 
an MCL on the other of 3 would be required. 
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Figure 3-21. The “risk surface” showing the relationship between confidence, risk, and 
the fraction of protected population to the target risk level at a given MCL. 
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 Table 3-10. MCL (µg/L) at target risk of 10-5
Fraction (F) of the Population with Pc< 10-5 (%) 
 100 90 80 70 60 50 
1 1 1 1 1 1 1 
0.9 1 1 1 1 1 1 
0.8 1 1 1 1 1 1 
0.7 1 1 1 1 1 1 
0.6 1 1 1 1 1 1 
Confidence 
(C) 
0.5 1 1 1 1 1 1 
 
Table 3-11. MCL (µg/L) at target risk of 10-4
Fraction (F) of the Population with Pc< 10-4 (%) 
 100 90 80 70 60 50 
1 1 1 3 3 3 3 
0.9 1 3 3 3 3 5 
0.8 1 3 3 3 5 5 
0.7 1 3 3 5 5 10 
0.6 1 3 5 5 10 10 
Confidence 
(C) 
0.5 1 5 5 10 10 20 
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 3.3. The Alternate Method of Quantification of Margin of Safety with Meta-Analysis 
Results 
 
In previous section (section 3.1), m nalys as pe ed to combine results 
from several epidemiological studies to get aggregated slope factors, which are shown in 
Fi anothe vious sec n, five t availa  models for calculating the arsenic 
risk from drinking r and it variabi  and u certainty were co sidered.  The 
comparisons of these m  meta-analysis are in Table 3-12 and Figure 
3-22.  From Figure 3-22, it is clear that the slope factors resulting from meta-analysis are 
located at the lower values from the fits to the Morales data, which will result in lower risk.  
odel, it was assumed here that the 
slope factor itself has a lognormal distribution, with a median value at the best estimate from 
the meta-analysis (i.e. 3 10-5).  
 
Table 3-12. Arsenic Slope Factors calculated from Meta-Analysis and of other Dose-
response Models (also Showing the Difference in Predicted Values of Pc at 10 µg/
MODELS Pc ([As]= 10 µg/L) EQUIVALENT SLOPE FACTORS 
eta-a is w rform
gure 3-9.  In r pre tio bes ble
wate s lity n  n
odels and the results from
Considering the uncertainty in choice of dose-response m
×
L) 
Meta-analysis (Upper-Bound) .29E-0 E-04 2 5 1.27
Meta-Analysis (Be timate) 7.35E-06 E-05 st-Es 3.00
Mitosis 1.00E-06 4.42E-06 
Repair 9.60E-05 4.25E-04 
NAS 2.00E-04 8.85E-04 
Linear New 3.50E-04 1.55E-03 
Upper Morales 6.00E-04 2.65E-03 
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Figure 3-22.  Risk of Bladder Cancer calculated from Different Slope Factors. 
 
3.3.1. Methods 
as follows: 
(1) It was assumed that the uncertainty distribution was lognormal, an y 
(2)  sole differ en the results in and the 
results usin ta-analysis is the emplo he meta-analysis r as the 
best estima er than the “Linear New” analysis.  Both of these used the linear 
models. 
(3) It was fu at the effect of usi er ividual 
dataset n 5, is to “shift” the dose-response curve for a given model 
The variation between models (or GSD for a lognormal distribution), was determined 
d so is characterized b
a median and GSD. 
 It was further assumed that the ence betwe  Section 5 
g the me yment of t slope facto
te, rath
rther assumed th ng the meta-analysis rath than the ind
 used in Sectio
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 downwards, and that the magnitude of this shift will be identical (which would be the 
case here, given the procedure by which the dose-response curves were fit to the original 
dataset). 
(4) As a result, if a given model (e.g. the Mitosis model) predicted a low-exposure risk a 
factor of X above or below the predictions of the “Linear New” model, it would similarly 
predict a factor of X above or below the linear fit of the meta-analysis. 
(5) As a further result, the GSD value obtained from the variation of predictions in Section 5 
would be the same as GSD value when these five models are “re-normalized” to the 
meta-analysis results. 
(6) The GSD for the variation in model predictions in Section 5 is approximately 2.2 (the 
preponderance of the models falling with a factor of 2.2 x 2.2 = 4.84 of the median value, 
which is the Linear New model.  So, this GSD is assumed to apply to the variation 
between model predictions obtained using the meta-analysis results). 
(7) The resulting uncertainty distribution for the slope factor, taking into account the meta-
analysis result and the variation between models, is lognormal with median of 3x10-5 and 
GSD of 2.2. 
With this uncertainty distribution on the slope factors, a nested variability-uncertainty 
analysis was conducted.  By using Crystal Ball, twenty different slope factors were sampled 
from the lognormal distribution with a median value of 3×10  and a GSD of 2.2.  Then we 
repeated the same variability analysis mentioned previously for each of these twenty sampled 
slope factors (p=0.05).  Twenty risk variability distributions at different MCLs then were 
generated.  The confidence that a given MCL produces at least F% of the population with a 
risk below Pc is the fraction of the sampled values of slope factor for which the resulting 
-5
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 var
whi
details of calculation steps.  
 
3.3.2. Results and Conclusions 
 
3.3
e new cumulative distribution function of confidence, and Figure 
the 
bec
met e ones used in the 
pro
24 was generated by extraction from Figure 3-23(a).  Assume the policy 
goal is 
iability distribution satisfies those criteria (i.e. the fraction of sampled slope factors for 
ch at least F% of the population has a risk below the target Pc).  Appendix B shows the 
 
.2.1. Confidence Analysis 
Figure 3-23(a) is th
3-23(b) is the same as the old one (identical to Figure 3-18), put here for comparison.  Note 
CDF at each MCL is shifted toward the upper left under these new results.  This is 
ause the slope factors used in the new analysis (which used the slope factor from the 
a-analysis as the median of an uncertainty PDF) are lower than th
previous analysis (which used only the Morales data).  Therefore, the confidence in 
tection increases under the same assumptions of MCL, F% and Pc. 
Figure 3-
to protect at least 90% of the population from a given risk level (10-4, 10-5, or 10-6).  
Using curves in Figure 3-24, it is easy to compare the confidence at different MCLs.  For 
example, at an MCL of 10 µg/L, the confidence is 1, 0.7, and 0 at risk levels of 10-4, 10-5, 
and10-6, respectively.  The confidence increases to 1, 0.95, 0.05 (at risk levels of 10-4, 10-5, 
and10-6, respectively) if the MCL is tightened to 5µg/L. 
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Figure 3-23. CDF (Confidence) of protecting 90% of the population at risk less than 
 
given Pc and at different MCLs by previous analysis and new analysis. 
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Figure 3-24. The Confidence that at least 90% of the population whose risk is below to 
the risk level (10-4, 10-5, or 10-6) at different MCLs (using meta-analysis). 
 
Figures 3-25 and 3-26 were generated by extraction from Figure 3-23(a), too.  They 
are presenting the same information as in Figure 3-24 from another perspective.  They 
illustrate the new confidence associated with fraction of the population below various target 
risk levels at different MCLs.    The figures generated from the previous analysis (using only 
Morales) are also put here for comparison. 
The graphs shown in Figures 3-25 illustrate the confidence associated with the claim 
10-6.  From these 
graphs, if the regulation target is that at least 90% of the population has a risk lower than 10-6, 
it can be seen that at MCLs from 50 to 10 µg/L, we have only a confidence of 0 that this goal 
will be met, but that the confidence increases to 0.05 when the MCL is set to 5 µg/L, 
that the fraction of the population below the target risk level at different MCLs is at least F%.  
The curves are shown in the situation of constraining target risk (or Pc) to 
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 increases to 0.15 when the MCL is set more stringently to 3 µg/L, and increases to 0.5 at 
MCL of 1 µg/L. 
Given the same policy goal (i.e., to protect 90% of the population), we can also 
compare the results of the new analysis (using meta-analysis) and the previous one (using 
Morales data).  At a risk level of 10-5, from Figure 3-26(b), we can see that the confidence 
ranges from 0.2 to 0.3 at MCLs varied from 50 to 1µg/L.  However, when the meta-analysis 
results are applied (see Figure 3-26(a)), an MCL equal to 50 µg/L produces a confidence of 
0.05 that this goal will be met, but the confidence increases to 0.7 when the MCL is set to 10 
µg/L and increases to almost 1 when the MCL is set more stringently to 1 µg/L. 
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population whose risk below to the risk level (10
Figure 3-25. The Relationship between Confidence and with the fraction of the 
-6) at different MCLs. 
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Figure 3-26. The relationship between Confidence and with the fraction of population 
whose risk below to various risk level (10-4 and 10-5) at different MCL. 
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 3.3.2.2. Risk Surfaces 
Figure 3-27 is the new series of “risk surface” to graphically present the relationships 
between Pc, F, C and MCL, one for each potential MCL.  As mentioned in section 3.2.6.1., 
reducing the MCL can be viewed in three ways from these surfaces: (i) it reduces the mean, 
or expectation, value of Pc in the population, and hence the expectation value of the total 
burden of effects; (ii) it increases the fraction F, conditional on target values of Pc and C; or 
(iii) it increases the confidence, C, in protection conditional on target values of Pc and F.  
Comparing with Figure 3-21, the new confidence associated with the fraction of the 
population below various target risk levels at different MCLs are higher.  Clearly, the effect 
of the meta-analysis is to greatly increase the confidence given the same fraction of protected 
population and risk target. 
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Figure 3-27. The “risk surface” showing the relationship between confidence, risk, and 
the fraction of protected population to the target risk level at a given MCL (by the new 
analysis with meta-analysis). 
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 3.3.2.3. MCL Tables 
The relationships among Pc, F, C and MCL can also be presented in a series of table 
(Table 3-13, 3-14, and 3-15) to clearly show what the decision (i.e. MCL) would be at given 
target risk and policy goal (i.e. a given confidence that a certain fraction of the population is 
being protected from this target risk). 
Considering that the policy goal is having confidence of 0.8 that at least 90% of the 
population is protected from the target risk (10-4, 10-5, and 10-6), the policy maker may ask: 
“What would decisions be like under this new framework employing fully probabilistic 
methods?”  For example, when the target risk is set to be 10-6 (Table 3-13), the MCL should 
be set 1µg/L to meet this policy goal; when the target risk is set to be 10-5 (Table 3-14), the 
MCL should be set 10µg/L to meet this policy goal; and when the target risk is set to be 10-4 
(Table 3-15), the MCL can be set higher than 50µg/L to meet this policy goal.  By using 
these tables, policy makers can choose a desirable MCL based on different policy goals. 
Comparing with the previous results of section 3.2.6.2, given the policy goal that 
having confidence of 0.8 that at least 90% of the population is protected from the target risk
(10-4 and 10-5), when the target risk is set to be 10-5, the MCL should be set 1 µg/L to meet 
this policy goal by previous analysis (Table 3-10), while the MCL should be set 10 g/L to 
meet this policy goal by new analysis considering the result of meta-analysis (Table 3-14).   
When the target risk is set to be 10-4 the MCL should be set 3 g/L to meet this policy goal by 
previous analysis (Table 3-10), while the MCL doesn’t need to be change from 50 µg/L to 
meet this policy goal by new analysis considering the result of meta-analysis (Table 3-15).  It 
is clear to see that by considering the result of meta-analysis, the arsenic MCLs are set to be 
 
less stringent by using MCL tables. 
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 From these new MCL tables, if the target risk is 10-6 (Table 3-13), it indicates that the 
current
ed from this target risk.  If the policy maker is willing 
to have
o an 
increas
 arsenic MCL of 10 µg/L may still be too high.  And at target risk of 10-5 (Table 3-14), 
arsenic MCL of 10 µg/L is  reasonable when the policy maker wants to have confidence of 
0.9 that 90% of the population is protected from this target risk, or have confidence of 0.5 
that 100% of the population is protect
 less confidence that less fraction of the population is protected from the target risk, 
then the arsenic MCL can be set less stringent.  Moreover, at target risk of 10-4 (Table 3-15), 
it indicates that the current arsenic MCL of 10 µg/L is too stringent. 
Therefore, from these MCL tables, it is possible for a policy maker to select a 
regulatory limit (MCL) that will provide a desired level of confidence that at least some pre-
specified fraction of the population (F) is below the pre-specified lifetime risk (Pc).  If an 
MCL fails to meet the desired confidence, the MCL may be lowered in order to gain the 
desired confidence.  This more stringent MCL then could be defended by referring t
ed confidence in meeting the goal of public health protection (although it does so at 
increased compliance cost). (Crawford-Brown, 2001) 
 
Table 3-13. MCL (µg/L) at target risk of 10-6
Fraction (F) of the Population with Pc< 10-6 (%) 
 100 90 80 70 60 50 
1 1 1 1 1 1 1 
0.9 1 1 1 1 3 3 
0.8 1 1 1 3 3 3 
0.7 1 1 1 3 3 3 
0.6 1 1 3 3 3 3 
Confidence 
0.5 1 1 3 3 3 3 
(C) 
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 Table 3-14. MCL (µg/L) at target risk of 10-5
Fraction (F) of the Population with Pc< 10-5 (%) 
 100 90 80 70 60 50 
1 1 3 3 3 3 5 
0.9 5 10 10 20 20 20 
0.8 5 10 20 20 20 20 
0.7 5 10 20 20 20 20 
0.6 5 20 20 20 20 20 
Confidence 
0.5 10 20 20 20 20 20 
(C) 
 
Table 3-15. MCL (µg/L) at target risk of 10-4
Fraction (F) of the Population with Pc< 10-4 (%) 
 100 90 80 70 60 50 
1 20 20 20 20 20 50 
0.9 50 >50 >50 >50 >50 >50 
0.8 50 >50 >50 >50 >50 >50 
0.7 50 >50 >50 >50 >50 >50 
0.6 50 >50 >50 >50 >50 >50 
Confidence 
0.5 50 >50 >50 >50 >50 >50 
(C) 
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 3.4. Price of Confidence 
 
3.4.1. Introduction 
Traditional approaches to establishing its on exposure to water-borne 
pollutants examine the dicted nu er of th ben  unde ariety scenar that 
are judged to include a safety in estimating risk.  While  appro , rooted in the 
precautionary principl s merit, oes no low th alyst to understand the in sed 
cost of compliance that can be associated with a given margin of safety. This can lead, in turn, 
ross different regulatory limits and, more 
troubling, to economic ine bring about 
improvements in the public health.  Therefore, the purpose of this m dolog  to 
understand the increased cost of compliance that can  
safety, and to developed to assess the re
protectiveness and the cost of com nce.  methodology elp licy ers 
know whether the inc d confid e, giv targe tion e po on p ed 
against an unacceptabl el of ris  worth ost.
 
3.4.2. Methods 
By linking with MCL, The annual compliance cost data were added as the third axis 
in Figures 3-25, 3-26(a) and 3-26(c).  They then became the 3-D graphs in Figures 3-28 (A, 
B and C).  These new graphs make it easier to see the relationships among Pc, F (presented 
by using Y here), C and cost.  The annual compliance cost data from the study of Gurian and 
Small (Gurian and Small, 2001) and  other two alternate cost estimates from different 
resources are summarized in Table 3-16.  
regulatory lim
 pre mb heal efits r a v  of ios 
 margin of  this ach
e, ha it d t al e an crea
to inconsistent degrees of protectiveness ac
fficiency in allocating limited resources to 
etho y is
be associated with a given margin of
lationship between different degrees of 
plia  This can h the po  mak
rease enc en a t frac  of th pulati rotect
e lev k, is  the c  
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 Table 3-16. Cost (per year) Associated with MCLs. 
Cost (M$/year) 
MCL (ppb) 
EPA Independent Researcher (Gurian and Small, 2001) AWWARF 
1 1000.0 2000.0 4500.0 
3 650.0 1050.0 3000.0 
5 400.0 700.0 1050.0 
10 200.0 300.0 600.0 
20 60.0 10.2 4.5 
Table Source: (Gurian and Small, 2001) 
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Figure 3-28. 3-D graphical presentations of the relationships among confidence, the 
fraction of the population being protected at the target risk levels of 10-6(A), 10-5(B) 
and 10-4(C), and Costs. 
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 3.4.3. Results and Conclusions 
A new research question can be addressed by linking the previous analyses to cost 
data: What is the incremental cost associated with an incremental increase in the margin 
of safety, characterized by an increase in C (confidence) and increase in F (fraction of the 
population protected from a risk of Pc)?  The results are presented by an example of a 
regulatory scenario to see if the cost associated with the stricter MCL can be justified by 
increased confidence.  Assume a regulator wishes that at least 90% of population is below a 
risk of 10-5.   By using the cost data of Gurian et al. (2001), the result is shown in Table 3-17. 
In Table 3-17, the third column is the incremental change in confidence derived from 
the Confidence column, and the fifth column is the incremental change in cost derived from 
the Cost column.  They are also shown in Figure 3-29.  Dividing incremental Cost by 
incremental Confidence, we can get the price of confidence, which is the sixth column.  This 
column exhibits the incremental annual cost required in order to increase confidence by 1%.  
The price of confidence is also shown in Figure 3-30.  Decision-makers can use the price of 
confidence as a regulatory tool to select a regulatory limit (MCL) that character es the 
increases in F and C, and the decrease in Pc (and hence increase in total health benefits), 
“purchased” by the cost of a given MCL. 
Table 3-17. Calculation of Price of Confidence (for a regulatory scenario that at least 
90% of the population is below a risk of 10-5) 
MCL 
(ppb) 
Confidence Incremental 
Confidence
Cost 
(Million 
$/year) 
Incremental Cost 
(Million $/year) 
Price of Confidence 
(Million$/year/Confidence)
iz
50 5.5% - 0.0   
20 28% 22.5% 10.2 10.2 45.33 
10 70% 42% 300.0 289.8 690.00 
5 93% 23% 700.0 400.0 1739.13 
3 100% 7% 1050.0 350.0 5000.00 
1 i 100% 0% 2000.0 950.0 Inf nite 
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Figure 3-29. The Confidence of protecting 90% of population below risk of 10-5 
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 The implication of this result is that we can compare the price of confidence among 
different MCL policies.  Assume a regulator wishes that at least 90% of population is below 
a risk of 10-5.  From Figure 3-30 we can clearly see the price of confidence of lowering 
arsenic from one MCL to another MCL.  Since there is no difference in confidence at MCLs 
from 3 to 1 µg/L, the incremental change in confidence is 0, making the price of confidence 
infinite.  Therefore, this suggests that the cost of lowering the MCL from 3 to 1 could not be 
justified by a confidence increase.  The lowest price of confidence falls into the range of 
lowering the MCL from 50 to 20 µg/L (0.45 million dollars per year per percent increase in 
confidence), while the one from 5 to 3 µg/L increases to 50 million dollars per year per 
percent increase in confidence.   
ng 
the incremental confidence and cost, it simply calculates the increase of confidence and cost 
associated with lowing the MCL from the original 50 µg/L.  Then the increased cost is 
divided by increased confidence, resulting in the increased annual cost required in order to 
increase confidence by 1%.  From Figure 3-31, we can see that the highest price of 
confidence is associated with the policy of lowering arsenic MCL from 50 to 1 µg/L, while 
the lowest one is the policy of lowering arsenic MCL from 50 to 20 µg/L.  If the policy goal 
falls into this range of MCLs, these two different ways of illustrating the price of confidence 
offers a quantitatively useful reasoning tool to make decisions. 
Figure 3-31 is another way of interpret the price of confidence.  Instead of calculati
 
114
 0.45
8.00
21.16
11.11
0
5
15
20
25
50->20 50->10 50->5 50->3 50->1
Pr
i
 o
f 
on
f
en
c
ill
in
/y
e
r/C
o
fid
e
e)
4 .65
10
MCL (ppb)
ce
C
id
e
(M
$
a
n
nc
 
Figur
90% of population is below a risk of 10 ) 
e 3-31. Price of Confidence of each policy (for a regulatory scenario that at least 
-5
 
115
  
 
CHAPTER 4 DISCUSSIONS 
 
4.1. Conclusions 
Ingestion of drinking water containing inorganic arsenic has become a matter of great 
public health concern, both in the United States and globally.  Inorganic arsenic in drinking 
water can exert both cancerous and non-cancer effects after acute or chronic exposures.  The 
US EPA reconsidered the exposure limits for arsenic in both community water systems and 
non-transit non-community water systems, and established a health-based, non-enforceable 
M  of zero µg/L and an enforceable Maximum 
Contaminant Level (MCL) of 10 µg/L based on data in NRC reports in 1999 and 2001. 
The purposes of this study were (1) to improve the current dose-response assessment 
for arsenic by performing and incorporating the results of a meta-analysis, (2) to understand 
margin of safety as it relates to uncertainty and variability, and to understand how an 
increasing margin of safety relates to the cost of a regulation, and (3) to develop a new 
framework of risk-based decision-making by characterizing probabilistically the variability 
and uncertainty in risk assessment, using arsenic as an example. 
The primary question in this research concerns the MCL of arsenic that may be 
allowed if a decision-maker wishes to claim that a reasonable fraction of the population (F) is 
protected below any given value of excess lifetime cancer risk (Pc) at any selected level of 
confidence (C).  The graphical and tabular presentations of the relationship among Pc, F, C 
and MCL provided here help to address this issue.  The price of confidence also offers a 
aximum Contaminant Level Goal (MCLG)
 
 quantitatively useful reasoning tool to make decisions.  Finally, this study incorporates these 
methodologies into the traditional risk assessment framework to develop a new framework of 
fully probabilistic risk assessm riability and uncertainty into 
the ass nment of margins of safety in risk assessment, and to help further decision-making. 
4.1.1. Using Meta-Analysis in Dose-Response Assessment 
A meta-analysis of arsenic studies was conducted by combining several 
epidemiological studies from different regions (such as Taiwan, US, Argentina, Chile and 
Finland) to produce a composite dose-response relationship between the amount of arsenic 
exposure and the excess probability of cancer.  Both the fixed-effect and random-effect 
models were used to calculate the averaged coefficient of the linear-logistic regression model.  
A homogeneity test was conducted first to check the heterogeneity among these studies.  
Because the heterogeneity was found to be high, a random-effect model had to be used.  This 
results in a wider confidence interval of slopes and a more conservative upper bound 
quantitative summary of risk.  The high heterogeneity shows that there are large 
differences between studies, which tells us it may not be appropriate to simply 
extrapolate from Taiwanese studies to the U.S.  The final product is an aggregated dose-
response model in the range of empirical observation of arsenic.  The best estimate of the 
slope factor from the meta-analysis is 3.0
ent to explicitly incorporate va
ig
 
× 10-5 (with unit of probability per 
microgram/kg/day), with the upper bound of 1.27×10-4.  These slope factors from the 
meta-analysis are lower than the ones from the EPA (1.15× 10-3) and NRC (8.85× 10-4).  
There clearly are large differences between the current study and the EPA/NRC results.  The 
possible reason for the difference is because EPA/NRC conducted their study mainly based 
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 on data from Taiwan, while in this study, meta-analysis was used to combine data from 
several different regions. 
Considering the most recent arsenic MCL (i.e. 10µg/L), the associated bladder 
cancer risk (lifetime excess probability) conducted using the upper bound result of the 
meta-analysis is 2.29 10-5 (7.35× ×10-6 if using the best estimate), which is much lower 
cancer for U.S. Populations 
(1.2
e o
than NRC’s theoretical lifetime excess risk of bladder 
×10-3 for female and 2.3×10-3 for male).  This result shows that the existing estimates 
of risk of bladder cancer provided by the EPA and NRC may be overestimates.  From the 
upper bound result of meta-analysis, the arsenic concentration corresponding to a lifetime 
excess probability of 10-3 is approximately 160 µg/L; the concentration corresponding to 10-4 
is approximately 40 µg/L; and the concentration corresponding to 10-5 is 4.5 µg/L. 
 
4.1.2. The Quantification of Margin of Safety 
Due to variability and uncertainty issues surrounding even the best method for 
estimating risks from arsenic, an arsenic MCL should be selected to provide a margin of 
safety.  The regulatory rationality employed in this research is to identify an MCL that 
provides some pre-specified level of confidence that at least a certain fraction of the 
population will be protected against a target level probability of cancer by a proposed 
regulatory action. 
In this study, five best available linear dose-response models were first used for 
variability and uncertainty analysis.  Then the results of the m ta-analysis were incorp rated 
into this probabilistic framework for considering the uncertainty of dose-response models; 
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 the new relationships among Pc, F, C and MCL are provided (see Figure 3-23, 3-24, 3-25 and 
3-26). 
The relationships among Pc, F, C and MCL are significantly different without 
the meta-analysis (previous analysis) and with the meta-analysis (new analysis).  As for 
the cumulative distribu ion functio s (CDF) of confidence, the new CDFs at each MCL are 
shifted toward the upper left when the meta-analysis results are used.  This is because the 
slope factors used in the new analysis (which used the slope factor from the meta-analysis as 
the median of an uncertainty PDF) are lower than the ones used in the previous analysis 
(which used only the Morales data).  Therefore, the confidence in protection increases 
under the same assumptions of MCL, F% and Pc when the meta-analysis results are 
incorporated (see Figure 3-23). 
t n
For example, assume a regulator wishes that at least 90% of the population is below a 
ta-analysis, the confidence ranged from 0.2 
to 0.3 
et, and the confidence gradually increases to 0.4 when the MCL is set to 5 
µg/L a
risk of 10-5.  In the previous analysis without me
at MCLs varied from 50 to 1 µg/L.  However, when the meta-analysis results are 
applied, an MCL equal to 50 µg/L produces a confidence of 0.05 that this goal will be met, 
but the confidence increases to 0.7 when the MCL is set to 10 µg/L and increases to almost 1 
when the MCL is set more stringently to 1 µg/L.  At the risk target of 10-4, in the previous 
analysis without meta-analysis, an MCL equal to 50 µg/L produces a confidence of 0.2 that 
this goal will be m
nd increases to almost 0.9 when the MCL is set more stringently to 1 µg/L.  In the new 
analysis with meta-analysis, the confidence ranged from 0.9 to 1 at MCLs from 50 µg/L to 1 
µg/L (see Figure 3-19, Figure 3-24, and Figure 3-26).  Clearly, the effect of the meta-
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 analysis is to greatly increase the confidence that MCLs of between 1 and 50 µg/L will 
be protective at arsenic level of 10-5 or 10-4. 
 issue. 
This research then generated two policy tools that can be applied in selecting an 
MCL: (1) risk surfaces and (2) MCL tables. 
 
(1) Risk Surfaces 
The primary policy question concerns the MCL of arsenic that may be allowed if a 
decision-maker wishes to claim that a reasonable fraction of the population (F) is protected 
below any given value of excess lifetime cancer risk (Pc) at any selected level of confidence 
(C).  The graphical and tabular presentations of the relationships among Pc, F, C and MCL 
provided here help to address this
Using arsenic in drinking water as an example, a methodology of probabilistic risk 
assessment was developed to depict “risk surfaces” relating candidate MCLs to the excess 
lifetime probability of cancer following exposure (Pc), the fraction (F) of the exposed 
population at or below this probability, and the confidence (C) that this fraction does not 
exceed any pre-specified target fraction.  From a series of surfaces (see Figure 3-21), one for 
each potential MCL, reducing the MCL can be viewed in three ways: (i) it reduces the mean, 
or expectation, value of Pc in the population, and hence the expectation value of the total 
burden of effects; (ii) it increases the fraction F, conditional on target values of Pc and C; or 
(iii) it increases the confidence, C, in protection conditional on target values of Pc and F.  
Also, this probabilistic framework for assessing the risk surfaces associated with different 
MCLs provides decision-makers a regulatory tool to select a regulatory limit (MCL) that 
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 characterizes the increases in F and C, and the decrease in Pc (and hence increase in total 
health benefits), “purchased” by the cost of a given MCL. 
C
 the fraction of population below various target 
risk levels at different MCLs are higher.  Clearly, the effect of the meta-analysis is to 
e confidence given the same fraction of protected population and risk 
target.
alysis, or Table 3-31, 3-14, and 3-15 with meta-
analysi
0.8 that at least 90% of the population is protected from the target risk (10-4 and 10-5), when 
omparing Figure 3-21 (without meta-analysis) with Figure 3-27 (with meta-
analysis), the new confidence associated with
greatly increase th
 
 
(2) MCL Tables 
The relationships among Pc, F, C and MCL can be presented in a series of table 
(Table 3-10 and 3-11 without meta-an
s) to clearly show what the MCL would be at given target risk and policy goal (i.e. a 
given confidence that a certain fraction of population is being protected from this target risk).  
If consider the MCL tables with meta-analysis and assuming the policy maker sets the policy 
goal of having confidence of 0.8 that at least 90% of the population is protected from the 
target risk:  when the target risk is set to be 10-6, the MCL should be set 1µg/L to meet this 
policy goal; when the target risk is set to be 10-5, the MCL should be set 10µg/L to meet this 
policy goal; and when the target risk is set to be 10-4, the MCL can be set higher than 50µg/L 
to meet this policy goal (Table 3-13, 3-14, and 3-15).  By using these tables, policy makers 
can choose a desirable MCL based on different policy goals. 
Table 4-1 shows the comparison of difference choices in MCLs by study without 
meta-analysis and  study with meta-analysis.  Given the policy goal that having confidence of 
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 the target risk is set to be 10-5, the MCL should be set 1 µg/L to meet this policy goal by 
previous analysis (Table 3-10), while the MCL should be set 10 g/L to meet this policy goal 
by new
 considering the result of meta-analysis, the arsenic MCLs are set to be less 
stringent by using MCL tables. 
Table 4
 analysis considering the result of meta-analysis (Table 3-14).   When the target risk is 
set to be 10-4 the MCL should be set 3 g/L to meet this policy goal by previous analysis 
(Table 3-11), while the MCL doesn’t need to be change from 50 µg/L to meet this policy 
goal by new analysis considering the result of meta-analysis (Table 3-15). It is clear to see 
that by
 
-1 Comparison of MCLs (µg/L) (Given the Policy Goal that having Confidence 
of 0.8 that at least 90% of the Population is Protected from the Target Risk) 
 Without Meta-Analysis With Meta-Analysis 
Target Risk  (Pc) MCL (µg/L) MCL (µg/L) 
10-6 - 1 
10-5 1 10 
10 3 >50 -4
 
 
4.1.3. Price of Confidence 
Another policy question concerns whether the increased confidence that a target 
fraction of the population is protected against an unacceptable level of risk is worth the cost.  
The price of confidence was developed here to offer a quantitatively useful reasoning tool to 
answer the question: What is the incremental cost associated with an incremental increase in 
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 the margin of safety, characterized by an increase in C (confidence) and increase in F 
(fraction of population protected from a risk of Pc)?   
Assuming a regulator wishes that at least 90% of the population is below a risk of 10-5, 
and using the cost data of Gurian et al. (2001), the price of confidence offers a quantitatively 
useful reasoning tool to make decisions (see Table 3-17, Figure 3-30 and 3-31).  By using the 
marginal method, the lowest price of confidence is found when the MCL is lowered from 50 
to 20 µg/L (0.45 million dollars per year per percent increase in confidence), while the price 
of moving from 5 to 3 µg/L increases to 50 million dollars per year per percent increase in 
confidence, and the price per percent increase in confidence of lowering the MCL from 3 to 1 
e 
ated with a 
policy that lowers the arsenic MCL from
is associated with lowering the arsenic MCL from 50 to 1 µg/L.  Both of these methods 
suggest that the lowest price of confidence, i.e. the lowest incremental cost associated with 
an incremental increase in the confidence of public health protection, is associated with the 
policy of lowering the arsenic MCL from 50 to 20 µg/L.  Therefore, according to the results 
of the price of confidence analysis here, lowering the arsenic MCL from 50 to 20 µg/L is the 
population will be below a target risk.  Then, the cost associated with each MCL may be 
was essentially infinite.  If we would like to compare different policies (i.e. lowering th
MCL from 50 µg/L to another MCL), the lowest price of confidence is associ
 50 to 20 µg/L, while the highest price of confidence 
optimal policy. 
By applying the concept of the price of confidence, decision-makers should be able 
to understand the costs associated with MCLs aimed at protecting against unacceptable 
residual health risks with some margin of safety.  They may first characterize the degree to 
which a regulatory decision produces reasonable confidence that a reasonable majority of the 
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 taken into account in striving for greater protection of health both by providing an ample 
margin of safety and by requiring the least cost to produce an increase in this margin of 
safety. 
 
4.2.1. Using Meta-Analysis in Dose-Response Assessment 
One limitation of this study is that there are only seven observational studies available 
for meta-analysis.  The very few available data make it difficult to do further investigation, 
such as meta-regression to check whether an overall study result varies among subgroups (e.g. 
study type or location), or a sensitivity analysis to detect the robustness of the findings to 
different assumptions.  New observational studies of arsenic, especially ones involving a 
case-control or cohort design, are critical but require the investment of large amounts of 
money and time.  Still, meta-analysis has proven here to be an appropriate tool to resolve the 
discrepancies among existing epidemiological data, and to produce a reasonable generalized 
 Within these broad constraints, there remains a wide degree of flexibility in 
interpreting whether a particular decision is rational and justified. 
 
The results generated from Price of Confidence may look different with the ones 
generated from the Quantification of Margin of Safety.  This is because they are illustrated 
by different perspectives in which the policy goals are stated.  Separately, these two 
methodologies can be policy tools, while putting them together, it can be a framework for 
risk-based decision making. 
 
 
4.2. Limitations, Contributions and Future Research 
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 dose-response model and its distribution of parameters.  The precision of meta-analysis can 
be improved when more observational studies in various regions of the world are done in the 
future. 
This methodology can also be applied to other internal cancers from arsenic or other 
contam ants.  However, considering that bladder cancer is the controlling effect for arsenic 
regulat
4.2.2. The Quantification of Margin of Safety 
To incorporate several model inputs contributing inter-subjective variability (in 
parameter values, activity patterns, etc) or uncertainty (in modeling, parameter values and 
ptions had to be 
made.  Some of these assumptions are not yet fully supported as described below and will 
 
in
ion and that there are fewer observational studies available for other internal cancers, 
it is unlikely that the results developed here would change significantly if other cancers were 
considered. 
 
low-dose extrapolation, etc) in characterizing margin of safety, several assum
require future research to improve on them. 
(1) Inter-subjective variability 
No inter-subject variations in water concentration (Cw) and in exposure duration 
were assumed (a lifetime exposure of 75 years is assumed).  The first assumption was made 
because only exposure at the MCL was examined; the latter one was made because data on 
which alternative associations might be based were unavailable. 
 
(2) Uncertainty 
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 A benchmark dose approach was adopted in which (1) a best fit of each separate 
model to the data was obtained; (2) the model was used to estimate the value of Pc at 10 µg/L; 
and (3) a linear function (characterized by a slope factor) was fit between the origin and this 
benchm
 the risk, especially at low doses for the Mitosis and Repair models.  Other kinds 
of dose-response shapes should also be considered in the future.  Also, in the analysis 
without meta-analysis, only five best available models were chosen for the consideration of 
model uncertainty.  These five models may not be able to represent fully the distribution of 
models, and the approximated GSD derived from these five models may be changed if 
additional models were considered.  More kinds of models should be incorporated in further 
studies, at least until the mechanism of action for arsenic is better understood. 
 
With some limitations in mind, this new framework of risk-based decision-making 
does improve understanding of variability and uncertainty issues in risk assessment, provides 
a useful way to quantify the margin of safety, and helps to select optimal regulatory limits 
under given constraints.  This new framework of risk-based decision-making provides a 
useful policy tool which can be applied coherently across the regulation decisions for 
different contaminants.  It can also provide a consistent scientific application of the human 
health risk assessment, including the calculation of risk, the characterization of inter-
subjective variability and the characterization of uncertainty. 
ark as an approximation to the low-dose behavior of the dose-response curve for that 
model.  However, some uncertainty problems can still not be eliminated by using this 
benchmark dose approach.  First, linear models characterized by slope factors were the only 
dose-response models considered in this study at low levels of exposure.  This may 
overestimate
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 APPENDIX A. Risk Calculation 
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 APPENDIX B. Rick Calculation using Meta-Analysis Results 
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